Trial Outcomes & Findings for A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain (NCT NCT01571362)

NCT ID: NCT01571362

Last Updated: 2017-04-04

Results Overview

Weekly average diary NRS-Pain scores were derived from the daily NRS-pain scale and calculated as the mean of the last 7 days. NRS-Pain scores based on an 11-point numerical rating scale from 0 (no pain) to 10 (worst possible pain). Higher scores indicate greater pain.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

410 participants

Primary outcome timeframe

Weeks 11 and 12

Results posted on

2017-04-04

Participant Flow

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Determine the Efficacy and Safety of ALO-02 Extended-Release Capsules in participants with Moderate to Severe Chronic Low Back Pain

A total of 410 participants were enrolled into the Open-Label Conversion and Titration Period and 281 participants were randomized into the Double-Blind Treatment Period, of which, 280 participants received study treatment.

Participant milestones

Participant milestones
Measure
Open ALO-02
Participants received AL0-02 extended-release capsules, orally (PO), twice daily (BID), at total daily doses of oxycodone from 20 to 160 milligrams (mg) in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator.
ALO-02 To Placebo
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Open-Label Conversion + Titration Period
STARTED
410
0
0
Open-Label Conversion + Titration Period
COMPLETED
281
0
0
Open-Label Conversion + Titration Period
NOT COMPLETED
129
0
0
Double-Blind Treatment Period
STARTED
0
134
146
Double-Blind Treatment Period
COMPLETED
0
81
107
Double-Blind Treatment Period
NOT COMPLETED
0
53
39

Reasons for withdrawal

Reasons for withdrawal
Measure
Open ALO-02
Participants received AL0-02 extended-release capsules, orally (PO), twice daily (BID), at total daily doses of oxycodone from 20 to 160 milligrams (mg) in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator.
ALO-02 To Placebo
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Open-Label Conversion + Titration Period
Withdrawal by Subject
11
0
0
Open-Label Conversion + Titration Period
Protocol Violation
7
0
0
Open-Label Conversion + Titration Period
Adverse Event
57
0
0
Open-Label Conversion + Titration Period
Lost to Follow-up
10
0
0
Open-Label Conversion + Titration Period
Does not meet entrance criteria
41
0
0
Open-Label Conversion + Titration Period
Other - unspecified
3
0
0
Double-Blind Treatment Period
Withdrawal by Subject
0
11
5
Double-Blind Treatment Period
Protocol Violation
0
8
9
Double-Blind Treatment Period
Adverse Event
0
9
14
Double-Blind Treatment Period
Lost to Follow-up
0
3
6
Double-Blind Treatment Period
Insufficient clinical response
0
16
4
Double-Blind Treatment Period
Other - unspecified
0
6
1

Baseline Characteristics

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Open ALO-02
n=410 Participants
Participants received AL0-02 extended-release capsules, orally PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator.
Age, Customized
Between 18 and 65 years
364 Participants
n=99 Participants
Age, Customized
>=65 years
46 Participants
n=99 Participants
Sex: Female, Male
Female
233 Participants
n=99 Participants
Sex: Female, Male
Male
177 Participants
n=99 Participants

PRIMARY outcome

Timeframe: Weeks 11 and 12

Population: Intent-to-Treat (ITT) Population: all participants who were randomized into the Double-Blind Treatment Period and received at least 1 dose of study drug after randomization; the averaged value for each participant from the 100 imputed datasets were used. Hybrid multiple and single imputation were applied, depending on reason for discontinuation.

Weekly average diary NRS-Pain scores were derived from the daily NRS-pain scale and calculated as the mean of the last 7 days. NRS-Pain scores based on an 11-point numerical rating scale from 0 (no pain) to 10 (worst possible pain). Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=133 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=145 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change in Weekly Average Electronic Diary (eDiary) Numeric Rating Scale -Pain (NRS-Pain) Score From Randomization Baseline to Final 2 Weeks (Average of Weeks 11 and 12)
1.23 Units on a Scale
Standard Error 0.179
0.60 Units on a Scale
Standard Error 0.168

SECONDARY outcome

Timeframe: Week 12

Population: ITT Population; imputation using last observation carried forward (LOCF) method.

The RMDQ is a 24-item questionnaire designed to measure self-rated disability due to back pain. An individual participant's score can vary from 0 (no disability) to 24 (severe disability), with a lower score indicating better function; higher score indicating greater disability.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=118 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=122 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change in Roland-Morris Disability Questionnaire (RMDQ) Total Score From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit).
0.50 Units on a Scale
Standard Error 0.404
0.67 Units on a Scale
Standard Error 0.393

SECONDARY outcome

Timeframe: Randomization Baseline, Week 12

Population: ITT Population; percentage based on the number of participants who had non-missing values at Randomization Baseline and Week 12/early termination for each treatment. Imputation using LOCF method.

Measure represents the score at Randomization Baseline / score at Week 12 (or Early Termination) in PGA, a global evaluation that utilizes a 5-point Likert scale with a score of 1 being the best (Very Good) and a score of 5 being the worst (Very Poor).

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=130 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=137 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Good / Very Good
5.4 Percentage of participants
11.7 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Good / Good
6.2 Percentage of participants
2.9 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Good / Fair
1.5 Percentage of participants
1.5 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Good / Poor
0.8 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Good / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Good / Very Good
6.2 Percentage of participants
3.6 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Good / Good
18.5 Percentage of participants
19.7 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Good / Fair
4.6 Percentage of participants
6.6 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Good / Poor
0.0 Percentage of participants
0.7 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Good / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Fair / Very Good
3.1 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Fair / Good
17.7 Percentage of participants
21.2 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Fair / Fair
23.1 Percentage of participants
26.3 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Fair / Poor
0.8 Percentage of participants
2.2 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Fair / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Poor / Very Good
0.8 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Poor / Good
2.3 Percentage of participants
1.5 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Poor / Fair
4.6 Percentage of participants
2.2 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Poor / Poor
1.5 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Poor / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Poor / Very Good
0.0 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Poor / Good
1.5 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Poor / Fair
1.5 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Poor / Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage (%) of Participants With Shift in Patient Global Assessment (PGA) by Category With Baseline PGA Score of Very Good (1), Good (2), Fair (3), Poor (4), Very Poor (5) From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit).
Very Poor / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants

SECONDARY outcome

Timeframe: Weeks 11 and 12

Population: ITT Population

Weekly average Diary NRS-pain scores are derived from the daily pain NRS and calculated as the mean of the last 7 days. Scores range from 0 equals (=) no pain to 10 = worst possible pain. Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction of Greater or Equal to (≥) 20%
48.5 percentage of participants
62.3 percentage of participants

SECONDARY outcome

Timeframe: Weeks 11 and 12

Population: ITT Population

Weekly average Diary NRS-pain scores are derived from the daily pain NRS and calculated as the mean of the last 7 days. Scores range from 0 = no pain to 10 = worst possible pain. Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction ≥30%
44.0 percentage of participants
57.5 percentage of participants

SECONDARY outcome

Timeframe: Weeks 11 and 12

Population: ITT Population

Weekly average Diary NRS-pain scores are derived from the daily pain NRS and calculated as the mean of the last 7 days. Scores range from 0 = no pain to 10 = worst possible pain. Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction ≥40%
35.1 percentage of participants
50.7 percentage of participants

SECONDARY outcome

Timeframe: Weeks 11 and 12

Population: ITT Population

Weekly average Diary NRS-pain scores are derived from the daily pain NRS and calculated as the mean of the last 7 days. Scores range from 0 = no pain to 10 = worst possible pain. Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Improvement in Weekly Average eDiary NRS-Pain Scores From Screening to Final 2 Weeks of the Double-Blind Treatment Period (Average of Weeks 11 and 12) by Cumulative Percent Reduction ≥50%
29.9 percentage of participants
39.7 percentage of participants

SECONDARY outcome

Timeframe: Screening, Week 4, 5, or 6

Population: Titration Period Safety Population: defined as all participants who received any amount of ALO-02 capsules during the Open-Label Conversion and Titration Period; imputation using the LOCF method. n=number of participants contributing to the mean for the specified parameter.

BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain. Pain Severity Index is the mean of the 4 pain scores (worst, least, average, and right now) on the BPI-sf; range is 0=No pain to 10=Pain as bad as you can imagine; A higher score indicates greater pain severity. Pain Interference Index is the mean of the scores for the 7 items of the BPI-sf; range is 0=Does not interfere to 10=Completely interferes.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Open-Label Treatment in Brief Pain Inventory - Short Form (BPI-sf): Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Worst Pain Score (n=400)
-3.3 Units on a Scale
Standard Deviation 2.30
Change From Screening Period to End of Open-Label Treatment in Brief Pain Inventory - Short Form (BPI-sf): Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Least Pain Score (n=400)
-2.6 Units on a Scale
Standard Deviation 2.33
Change From Screening Period to End of Open-Label Treatment in Brief Pain Inventory - Short Form (BPI-sf): Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Average Pain Score (n=400)
-3.0 Units on a Scale
Standard Deviation 2.11
Change From Screening Period to End of Open-Label Treatment in Brief Pain Inventory - Short Form (BPI-sf): Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Pain Right Now (n=400)
-3.3 Units on a Scale
Standard Deviation 2.41
Change From Screening Period to End of Open-Label Treatment in Brief Pain Inventory - Short Form (BPI-sf): Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Pain Severity Index (n=400)
-3.1 Units on a Scale
Standard Deviation 2.07
Change From Screening Period to End of Open-Label Treatment in Brief Pain Inventory - Short Form (BPI-sf): Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Pain Interference Index (n=401)
-2.8 Units on a Scale
Standard Deviation 2.32

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population - observed cases; n=number of participants assessed for the given parameter at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain. Pain Severity Index is the mean of the 4 pain scores (worst, least, average, and right now) on the BPI-sf; range is 0=No pain to 10=Pain as bad as you can imagine; A higher score indicates greater pain severity. Pain Interference Index is the mean of the scores for the 7 items of the BPI-sf; range is 0=Does not interfere to 10=Completely interferes.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=279 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to Randomization Baseline in BPI-sf: Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Worst Pain Score (n=279)
-4.2 units on scale
Standard Deviation 1.83
Change From Screening Period to Randomization Baseline in BPI-sf: Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Least Pain Score (n=279)
-3.4 units on scale
Standard Deviation 2.04
Change From Screening Period to Randomization Baseline in BPI-sf: Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Average Pain Score (n=279)
-3.8 units on scale
Standard Deviation 1.60
Change From Screening Period to Randomization Baseline in BPI-sf: Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Pain Right Now (n=279)
-4.2 units on scale
Standard Deviation 1.95
Change From Screening Period to Randomization Baseline in BPI-sf: Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Pain Severity Index (n=279)
-3.9 units on scale
Standard Deviation 1.63
Change From Screening Period to Randomization Baseline in BPI-sf: Worst Pain, Least Pain, Average Pain, Pain Right Now, Pain Severity Index, Pain Interference Index
Pain Interference Index (n=279)
-3.4 units on scale
Standard Deviation 2.16

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for worst pain at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 2 (n=126,135)
1.00 Units on a Scale
Standard Error 0.160
0.38 Units on a Scale
Standard Error 0.155
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 4 (n=111,125)
1.15 Units on a Scale
Standard Error 0.179
0.51 Units on a Scale
Standard Error 0.168
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 8 (n=89,113)
0.86 Units on a Scale
Standard Error 0.205
0.49 Units on a Scale
Standard Error 0.180
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 12/Early Termination (ET)(n=131,138)
1.45 Units on a Scale
Standard Error 0.176
0.47 Units on a Scale
Standard Error 0.170

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation by LOCF; n=number of participants assessed for least pain at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 2 (n=126,135)
0.74 Units on a Scale
Standard Error 0.139
0.34 Units on a Scale
Standard Error 0.134
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 4 (n=111,125)
0.94 Units on a Scale
Standard Error 0.147
0.06 Units on a Scale
Standard Error 0.138
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 8 (n=89,112)
0.83 Units on a Scale
Standard Error 0.171
0.19 Units on a Scale
Standard Error 0.151
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 12/ET(n=131,138)
1.13 Units on a Scale
Standard Error 0.151
0.28 Units on a Scale
Standard Error 0.147

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for average pain at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 2 (n=125,135)
1.01 Units on a Scale
Standard Error 0.137
0.36 Units on a Scale
Standard Error 0.132
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 4 (n=111,124)
1.04 Units on a Scale
Standard Error 0.156
0.30 Units on a Scale
Standard Error 0.147
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 8 (n=88,112)
0.99 Units on a Scale
Standard Error 0.179
0.35 Units on a Scale
Standard Error 0.157
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 12/ET (n=131,138)
1.27 Units on a Scale
Standard Error 0.159
0.39 Units on a Scale
Standard Error 0.154

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for pain right now at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 2 (n=126,135)
1.04 Units on a Scale
Standard Error 0.149
0.40 Units on a Scale
Standard Error 0.144
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 4 (n=111,125)
1.03 Units on a Scale
Standard Error 0.157
0.24 Units on a Scale
Standard Error 0.148
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 8 (n=88,112)
1.04 Units on a Scale
Standard Error 0.200
0.33 Units on a Scale
Standard Error 0.176
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 12/ET (n=131,138)
1.43 Units on a Scale
Standard Error 0.166
0.36 Units on a Scale
Standard Error 0.161

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for pain severity index at the specified timepoint.

Pain Severity Index is the mean of the 4 pain scores (worst, least, average, and right now) on the BPI-sf; range is 0=No pain to 10=Pain as bad as you can imagine; a higher score indicates greater pain severity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 2 (n=125,135)
0.95 Units on a Scale
Standard Error 0.136
0.37 Units on a Scale
Standard Error 0.131
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 4 (n=111,124)
1.04 Units on a Scale
Standard Error 0.145
0.28 Units on a Scale
Standard Error 0.137
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 8 (n=88,112)
0.95 Units on a Scale
Standard Error 0.173
0.34 Units on a Scale
Standard Error 0.152
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 12/ET (n=131,138)
1.32 Units on a Scale
Standard Error 0.149
0.38 Units on a Scale
Standard Error 0.144

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for pain interference index at the specified timepoint.

Pain Interference Index is the mean of the scores for the 7 items of the BPI-sf; range is 0=Does not interfere to 10=Completely interferes.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 2 (n=126,135)
0.77 Units on a Scale
Standard Error 0.135
0.36 Units on a Scale
Standard Error 0.130
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 4 (n=111,127)
0.92 Units on a Scale
Standard Error 0.139
0.43 Units on a Scale
Standard Error 0.129
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 8 (n=89,113)
0.64 Units on a Scale
Standard Error 0.168
0.47 Units on a Scale
Standard Error 0.148
Change From Randomization Baseline to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 12/ET (n=131,138)
1.14 Units on a Scale
Standard Error 0.149
0.49 Units on a Scale
Standard Error 0.145

SECONDARY outcome

Timeframe: Weeks 2, 4, 8 and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for worst pain at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 2 (n=126,134)
-3.09 Units on a Scale
Standard Error 0.186
-3.80 Units on a Scale
Standard Error 0.181
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 4 (n=111,124)
-3.01 Units on a Scale
Standard Error 0.203
-3.74 Units on a Scale
Standard Error 0.192
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 8 (n=89,112)
-3.16 Units on a Scale
Standard Error 0.238
-3.72 Units on a Scale
Standard Error 0.212
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Worst Pain
Week 12/ET (n=131,137)
-2.63 Units on a Scale
Standard Error 0.207
-3.73 Units on a Scale
Standard Error 0.203

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for least pain at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 2 (n=126,134)
-2.55 Units on a Scale
Standard Error 0.162
-3.05 Units on a Scale
Standard Error 0.157
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 4 (n=111,124)
-2.40 Units on a Scale
Standard Error 0.171
-3.29 Units on a Scale
Standard Error 0.162
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 8 (n=89,111)
-2.44 Units on a Scale
Standard Error 0.199
-3.21 Units on a Scale
Standard Error 0.178
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Least Pain
Week 12/ET (n=131,137)
-2.14 Units on a Scale
Standard Error 0.175
-3.12 Units on a Scale
Standard Error 0.171

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for average pain at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 2 (n=125,134)
-2.63 Units on a Scale
Standard Error 0.154
-3.43 Units on a Scale
Standard Error 0.150
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 4 (n=111,123)
-2.76 Units on a Scale
Standard Error 0.172
-3.55 Units on a Scale
Standard Error 0.164
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 8 (n=88,111)
-2.71 Units on a Scale
Standard Error 0.205
-3.50 Units on a Scale
Standard Error 0.182
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Average Pain
Week 12/ET (n=131,137)
-2.39 Units on a Scale
Standard Error 0.176
-3.43 Units on a Scale
Standard Error 0.172

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for pain right now at the specified timepoint.

BPI-sf scores range from 0=No pain to 10=Pain as bad as you can imagine; higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 2 (n=126,134)
-3.12 Units on a Scale
Standard Error 0.170
-3.72 Units on a Scale
Standard Error 0.165
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 4 (n=111,124)
-3.15 Units on a Scale
Standard Error 0.187
-3.82 Units on a Scale
Standard Error 0.177
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 8 (n=88,111)
-3.00 Units on a Scale
Standard Error 0.232
-3.71 Units on a Scale
Standard Error 0.206
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Right Now
Week 12/ET (n=131,137)
-2.72 Units on a Scale
Standard Error 0.189
-3.74 Units on a Scale
Standard Error 0.186

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for pain severity index at the specified timepoint.

Pain Severity Index is the mean of the 4 pain scores (worst, least, average, and right now) on the BPI-sf; range is 0=No pain to 10=Pain as bad as you can imagine; a higher score indicates greater pain severity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 2 (n=125,134)
-2.83 Units on a Scale
Standard Error 0.157
-3.50 Units on a Scale
Standard Error 0.152
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 4 (n=111,123)
-2.83 Units on a Scale
Standard Error 0.172
-3.60 Units on a Scale
Standard Error 0.164
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 8 (n=88,111)
-2.80 Units on a Scale
Standard Error 0.205
-3.53 Units on a Scale
Standard Error 0.182
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Severity Index
Week 12/ET (n=131,137)
-2.47 Units on a Scale
Standard Error 0.174
-3.51 Units on a Scale
Standard Error 0.171

SECONDARY outcome

Timeframe: Weeks 2, 4, 8, and 12

Population: ITT Population - imputed values at early termination. Imputation using the LOCF method; n=number of participants assessed for pain interference index at the specified timepoint.

Pain Interference Index is the mean of the scores for the 7 items of the BPI-sf; range is 0=Does not interfere to 10=Completely interferes.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 2 (n=126,134)
-2.58 Units on a Scale
Standard Error 0.164
-2.99 Units on a Scale
Standard Error 0.160
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 4 (n=111,126)
-2.52 Units on a Scale
Standard Error 0.175
-2.99 Units on a Scale
Standard Error 0.164
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 8 (n=89,112)
-2.72 Units on a Scale
Standard Error 0.198
-2.87 Units on a Scale
Standard Error 0.176
Change From Screening to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in BPI-sf Scores of Pain Interference Index
Week 12/ET (n=131,137)
-2.24 Units on a Scale
Standard Error 0.176
-2.88 Units on a Scale
Standard Error 0.172

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 11 and 12

Population: ITT Population; linear interpolation was used for internal missing values, with addition of 0 to the AUC for missing values from early discontinuation.

NRS-Pain scores based on an 11-point numerical rating scale from 0 (no pain) to 10 (worst possible pain). AUC was calculated using daily change from Baseline scores from Baseline until the last dose date in the Double-Blind Treatment Period. AUC was calculated for each participant using the linear trapezoidal method. Higher scores indicate greater pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Area Under the Curve (AUC) of eDiary NRS-Pain Scores From Randomization Baseline to Final 2 Weeks of the Double-Blind Treatment Period (Weeks 11 and 12)
39.00 Change in units on a scale*days
Standard Error 7.914
11.25 Change in units on a scale*days
Standard Error 7.636

SECONDARY outcome

Timeframe: Daily from Day 1 of the Double-Blind Period through Week 12

Population: ITT Population

The amount of acetaminophen administered for each treatment during the Double-Blind Treatment Period. Average daily use calculated as: total dose of rescue medication during Double-Blind Period divided by the number of days in Double-Blind Period.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Average Daily Use of Rescue Acetaminophen (Milligrams Per Day [mg/Day]) During the Double-Blind Treatment Period
207.84 Average mg/day
Standard Error 36.436
203.97 Average mg/day
Standard Error 34.851

SECONDARY outcome

Timeframe: Screening, Week 4, 5 or 6

Population: Titration Period Safety Population; an event was defined as a participant with 20%, 30%, 40%, or 50% analgesic response from Screening.

The percentage of analgesic response is defined as: (rolling 7-day mean pain score during Titration Period - Screening Period pain intensity score) divided by Screening Period pain intensity score times100.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=398 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Participants with 20% Analgesic Response
85.2 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Participants with 30% Analgesic Response
78.9 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Participants with 40% Analgesic Response
67.3 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Participants with 50% Analgesic Response
49.7 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Week 4, 5, or 6

Population: Titration Period Safety Population; an event was defined as a participant with 20%, 30%, 40%, or 50% analgesic response from Screening.

The percentage of analgesic response is defined as: (rolling 7-day mean pain score during Titration Period minus (-) Screening Period pain intensity score) divided by Screening Period pain intensity score times 100. An event was defined as a participant with 20, 30, 40, or 50% analgesic response from Screening. If there was no event for a participant, time to the event was considered censored at Day 42 of the Titration Period or before Day 42 of the Titration Period at the time of the last diary pain score. The survival duration begins on the date of first dose of study drug in the Titration Period and is calculated as the \[date of event or last diary pain score - date of first dose in Titration Period +1\].

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=398 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Time to 20% Analgesic Response from Screening
15 days
Interval 14.0 to 17.0
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Time to 30% Analgesic Response from Screening
21 days
Interval 19.0 to 23.0
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Time to 40% Analgesic Response from Screening
28 days
Interval 26.0 to 30.0
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to End of Open-Label Treatment
Time to 50% Analgesic Response from Screening
35 days
Interval 32.0 to 38.0

SECONDARY outcome

Timeframe: Screening, Randomization Baseline (up to 6 weeks)

Population: ITT Population; an event was defined as a participant with 20%, 30%, 40%, or 50% analgesic response from Screening.

The percentage of analgesic response is defined as: (rolling 7-day mean pain score during Titration Period - Screening Period pain intensity score) divided by Screening Period pain intensity score times 100.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=278 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Participants with 20% Analgesic Response
99.3 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Participants with 30% Analgesic Response
95.3 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Participants with 40% Analgesic Response
86.0 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Participants with 50% Analgesic Response
64.0 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Randomization Baseline (up to 6 weeks)

Population: ITT Population; an event was defined as a participant with 20%, 30%, 40% or 50% analgesic response from Screening.

The percentage of analgesic response is defined as: (rolling 7-day mean pain score during Titration Period - Screening Period pain intensity score) divided by Screening Period pain intensity score times 100. If there was no event for a participant, time to the event was considered censored at Day 42 of the Titration Period or before Day 42 of the Titration Period at the time of the last diary pain score. The survival duration begins on the date of first dose of study drug in the Titration Period and is calculated as the \[date of event or last diary pain score - date of first dose in Titration Period +1\].

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=278 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Time to 20% Analgesic Response
14 days
Interval 13.0 to 16.0
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Time to 30% Analgesic Response
20 days
Interval 17.0 to 22.0
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Time to 40% Analgesic Response
26 days
Interval 23.0 to 28.0
Median Time to 20%, 30%, 40%, or 50% Analgesic Response From Screening Period to Randomization Baseline
Time to 50% Analgesic Response
33 days
Interval 30.0 to 35.0

SECONDARY outcome

Timeframe: Randomization Baseline, up to Week 12

Population: ITT Population; an event was defined as a participant with 20%, 30%, 40%, or 50% loss of analgesic response from Randomization Baseline.

The percentage of lost analgesic response is defined as: (rolling 7-day mean pain score during Double-Blind Period - Randomization Baseline pain intensity score) divided by Randomization Baseline pain intensity score times 100. If there was no event for a participant, time to the event was considered censored at Day 84 or before Day 84 at the time of the last diary pain score. The survival duration began on the date of first dose of study drug in the Double-Blind Period and was calculated as the \[date of event or last diary pain score - date of first dose in Double-Blind Treatment +1\].

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=132 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=143 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With a 20%, 30%, 40%, or 50% Loss of Analgesic Response From Randomization Baseline During the Double-Blind Treatment Period
Participants with 40% Loss of Analgesic Response
57.6 Percentage of participants
34.3 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Loss of Analgesic Response From Randomization Baseline During the Double-Blind Treatment Period
Participants with 50% Loss of Analgesic Response
50.8 Percentage of participants
31.5 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Loss of Analgesic Response From Randomization Baseline During the Double-Blind Treatment Period
Participants with 20% Loss of Analgesic Response
72.0 Percentage of participants
54.5 Percentage of participants
Percentage of Participants With a 20%, 30%, 40%, or 50% Loss of Analgesic Response From Randomization Baseline During the Double-Blind Treatment Period
Participants with 30% Loss of Analgesic Response
64.4 Percentage of participants
46.2 Percentage of participants

SECONDARY outcome

Timeframe: Randomization Baseline, up to Week 12

Population: ITT Population; an event was defined as a participant with 20%, 30%, 40%, or 50% loss of analgesic response from Randomization Baseline.

The percentage of lost analgesic response was defined as: (rolling seven day mean pain score during Double-Blind Period - Randomization Baseline pain intensity score) divided by Randomization Baseline pain intensity score times 100. If there was no event for a participant, time to the event was considered censored at Day 84 or before Day 84 at the time of the last diary pain score. The survival duration began on the date of first dose of study drug in the Double-Blind Period and was calculated as the \[date of event or last diary pain score - date of first dose in Double-Blind Treatment +1\].

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=132 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=143 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Time to 20%, 30%, 40%, or 50% Loss of Analgesic Response From Baseline During the Double-Blind Treatment Period
Time to 20% Loss of Analgesic Response
12 days
Interval 8.0 to 17.0
31 days
Interval 18.0 to
Number of participants with loss of response was too low to estimate the 95% confidence interval upper limit.
Median Time to 20%, 30%, 40%, or 50% Loss of Analgesic Response From Baseline During the Double-Blind Treatment Period
Time to 30% Loss of Analgesic Response
21 days
Interval 15.0 to 39.0
NA days
Interval 32.0 to
Number of participants with loss of response was too low to estimate the median time and 95% confidence interval upper limit.
Median Time to 20%, 30%, 40%, or 50% Loss of Analgesic Response From Baseline During the Double-Blind Treatment Period
Time to 40% Loss of Analgesic Response
41 days
Interval 21.0 to 61.0
NA days
Number of participants with loss of response was too low to estimate the median time and 95% confidence interval upper and lower limits.
Median Time to 20%, 30%, 40%, or 50% Loss of Analgesic Response From Baseline During the Double-Blind Treatment Period
Time to 50% Loss of Analgesic Response
62 days
Interval 24.0 to
Number of participants with loss of response was too low to estimate the 95% confidence interval upper limit.
NA days
Number of participants with loss of response was too low to estimate the median time and 95% confidence interval upper and lower limits.

SECONDARY outcome

Timeframe: Week 1 up to Week 12

Population: ITT Population; an event was defined as a participant with treatment discontinuation for investigator-reported lack of efficacy.

If there was no event for a participant, time to the event was considered censored at Day 84 or before Day 84 at time of treatment discontinuation for another reason.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants Discontinuing Treatment for Investigator-Reported Lack of Efficacy
11.9 Percentage of participants
2.7 Percentage of participants

SECONDARY outcome

Timeframe: Week 1 up to Week 12

Population: ITT Population; an event was defined as a participant with treatment discontinuation for investigator-reported lack of efficacy.

If there was no event for a participant, time to the event was considered censored at Day 84 or before Day 84 at time of treatment discontinuation for another reason. The survival duration begins on the date of first dose in the Double-Blind period and is calculated as the \[date of event or discontinuation - date of first dose in Double-Blind Period +1\].

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Time to Treatment Discontinuation for Investigator-Reported Lack of Efficacy During the Double-Blind Treatment Period
NA days
Incidence of discontinuation from investigator-reported lack of efficacy was too low to estimate median.
NA days
Incidence of discontinuation from investigator-reported lack of efficacy was too low to estimate median.

SECONDARY outcome

Timeframe: Screening, Weeks 1, 2, 3, 4, 5, and 6

Population: Titration Period Safety Population. Only participants with values at both Screening and each respective visit were included in the change from screening analysis; n=number of participants analyzed for the given parameter at the specified timepoint.

The COWS contains 11 common opiate withdrawal signs or symptoms rated by the investigator or designee who, for each item, checked the number that best described the participant's signs or symptoms. The minimum total COWS score is 0, the maximum is 48. Higher scores indicate a worse outcome. The summed score of the 11 items was used to assess a participant's level of opiate withdrawal.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Change from Screening at Week 3 (n=295)
-0.1 Units on a scale
Standard Deviation 1.21
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Screening (n=387)
0.6 Units on a scale
Standard Deviation 1.09
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Week 1 (n=353)
0.6 Units on a scale
Standard Deviation 1.04
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Change from Screening at Week 1 (n=333)
0.0 Units on a scale
Standard Deviation 1.20
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Week 2 (n=327)
0.5 Units on a scale
Standard Deviation 1.08
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Change from Screening at Week 2 (n=308)
0.0 Units on a scale
Standard Deviation 1.25
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Week 3 (n=316)
0.5 Units on a scale
Standard Deviation 0.92
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Week 4 (n=210)
0.6 Units on a scale
Standard Deviation 0.94
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Change from Screening at Week 4 (n=194)
0.0 Units on a scale
Standard Deviation 1.27
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Week 5 (n=138)
0.6 Units on a scale
Standard Deviation 0.82
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Change from Screening at Week 5 (n=131)
-0.1 Units on a scale
Standard Deviation 1.15
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Week 6/ET (n=375)
0.6 Units on a scale
Standard Deviation 0.99
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Change from Screening at Week 6 (n=352)
0.0 Units on a scale
Standard Deviation 1.28
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Maximum Titration Period (MTP) Value (n=375)
1.2 Units on a scale
Standard Deviation 1.42
Clinical Opiate Withdrawal Scale (COWS) Total Score During the Open-Label Titration Period
Change from screening to MTP Value (n=352)
0.6 Units on a scale
Standard Deviation 1.54

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 1, 2, 4, 8, and 12

Population: Double-Blind Safety Population. Only participants with values at both Randomization Baseline and each respective visit were included in the change from Randomization Baseline analysis; n=number of participants analyzed for the given parameter at the specified timepoint.

The COWS contains 11 common opiate withdrawal signs or symptoms rated by the investigator or designee who, for each item, checked the number that best described the participant's signs or symptoms. The minimum total COWS score is 0, the maximum is 48. Higher scores indicate a worse outcome. The summed score of the 11 items was used to assess a participant's level of opiate withdrawal.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
COWS Total Score During the Double-Blind Treatment Period
Randomization Baseline (n=134,146)
0.6 Units on a scale
Standard Deviation 0.85
0.4 Units on a scale
Standard Deviation 0.73
COWS Total Score During the Double-Blind Treatment Period
Week 1 (n=111,133)
0.8 Units on a scale
Standard Deviation 1.62
0.6 Units on a scale
Standard Deviation 1.13
COWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 1 (n=111,133)
0.3 Units on a scale
Standard Deviation 1.69
0.3 Units on a scale
Standard Deviation 1.12
COWS Total Score During the Double-Blind Treatment Period
Week 2 (n=115,128)
0.8 Units on a scale
Standard Deviation 1.28
0.7 Units on a scale
Standard Deviation 1.19
COWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 2 (n=115,128)
0.2 Units on a scale
Standard Deviation 1.45
0.3 Units on a scale
Standard Deviation 1.10
COWS Total Score During the Double-Blind Treatment Period
Week 4 (n=106,123)
0.6 Units on a scale
Standard Deviation 0.90
0.4 Units on a scale
Standard Deviation 0.66
COWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 4 (n=106,123)
0.1 Units on a scale
Standard Deviation 1.10
0.1 Units on a scale
Standard Deviation 0.79
COWS Total Score During the Double-Blind Treatment Period
Week 8 (n=87,107)
0.6 Units on a scale
Standard Deviation 1.02
0.6 Units on a scale
Standard Deviation 1.10
COWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 8 (n=87,107)
0.1 Units on a scale
Standard Deviation 1.03
0.2 Units on a scale
Standard Deviation 1.06
COWS Total Score During the Double-Blind Treatment Period
Week 12/ET (n=126,140)
0.7 Units on a scale
Standard Deviation 1.55
0.6 Units on a scale
Standard Deviation 1.17
COWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 12/ET(n=126,140)
0.2 Units on a scale
Standard Deviation 1.61
0.2 Units on a scale
Standard Deviation 1.21
COWS Total Score During the Double-Blind Treatment Period
Max. Double-Blind Period (DBP) Value (n=126,140)
1.4 Units on a scale
Standard Deviation 1.84
1.3 Units on a scale
Standard Deviation 1.60
COWS Total Score During the Double-Blind Treatment Period
Change from Baseline to max. DBP Value (n=126,140)
0.9 Units on a scale
Standard Deviation 1.90
0.9 Units on a scale
Standard Deviation 1.53

SECONDARY outcome

Timeframe: Follow-Up (FU) Weeks 1 and 2

Population: Double-Blind Safety Population. Only participants with values at both Randomization Baseline and each respective visit were included in the change from Randomization Baseline analysis; n=number of participants analyzed for the given parameter at the specified timepoint.

The COWS contains 11 common opiate withdrawal signs or symptoms rated by the investigator or designee who, for each item, checked the number that best described the participant's signs or symptoms. The minimum total COWS score is 0, the maximum is 48. Higher scores indicate a worse outcome. The summed score of the 11 items was used to assess a participant's level of opiate withdrawal.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=94 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=108 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
COWS Total Score During the Post-Treatment Period
Change from Baseline at FU Week 1 (n=68,83)
0.1 Units on a scale
Standard Deviation 0.90
0.2 Units on a scale
Standard Deviation 0.99
COWS Total Score During the Post-Treatment Period
FU Week 1 (n=68,83)
0.6 Units on a scale
Standard Deviation 0.72
0.6 Units on a scale
Standard Deviation 0.91
COWS Total Score During the Post-Treatment Period
FU Week 2 (n=78,91)
0.5 Units on a scale
Standard Deviation 0.70
0.9 Units on a scale
Standard Deviation 1.74
COWS Total Score During the Post-Treatment Period
Change from Baseline at FU Week 2 (n=78,91)
-0.1 Units on a scale
Standard Deviation 1.12
0.7 Units on a scale
Standard Deviation 1.83
COWS Total Score During the Post-Treatment Period
Max.FU Period Value (n=94,108)
0.7 Units on a scale
Standard Deviation 0.76
1.1 Units on a scale
Standard Deviation 1.67
COWS Total Score During the Post-Treatment Period
Change to max. FU Period Value (n=94,108)
0.1 Units on a scale
Standard Deviation 1.08
0.7 Units on a scale
Standard Deviation 1.74

SECONDARY outcome

Timeframe: Screening, Weeks 1, 2, 3, 4, 5, 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The COWS contains 11 common opiate withdrawal signs or symptoms rated by the investigator or designee who, for each item, checked the number that best described the participant's signs or symptoms. The minimum total COWS score is 0, the maximum is 48. The summed score of the 11 items was used to assess a participant's level of opiate withdrawal. The scores are assessed as follows: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Screening COWS less than(<)5 (n=387)
98.4 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Screening COWS=5-12 (n=387)
1.6 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 1 COWS <5 (n=353)
99.2 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 1 COWS=5-12 (n=353)
0.8 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 2 COWS <5 (n=327)
98.8 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 2 COWS 5-12 (n=327)
1.2 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 3 COWS <5 (n=316)
99.1 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 3 COWS 5-12 (n=316)
0.9 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 4 COWS <5 (n=210)
99.5 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 4 COWS 5-12 (n=210)
0.5 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 5 COWS <5 (n=138)
100 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 6 COWS <5 (n=375)
98.9 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Week 6 COWS 5-12 (n=375)
1.1 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Max. Titration Period Value COWS <5 (n=375)
96.8 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Open-Label Titration Period by COWS Category
Max. Titration Period Value COWS 5-12 (n=375)
3.2 Percentage of participants

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 1, 2, 4, 8, 12 (or Early Termination)

Population: Double-Blind Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The COWS contains 11 common opiate withdrawal signs or symptoms rated by the investigator or designee who, for each item, checked the number that best described the participant's signs or symptoms. The minimum total COWS score is 0, the maximum is 48. The summed score of the 11 items was used to assess a participant's level of opiate withdrawal. The scores are assessed as follows: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Max. DBP Value COWS 5-12 (n=126,140)
1.6 Percentage of participants
5.0 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Max. DBP Value COWS 13-24 (n=126,140)
0.8 Percentage of participants
0 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 2 COWS <5 (n=115,128)
99.1 Percentage of participants
98.4 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 2 COWS 5-12 (n=115,128)
0.9 Percentage of participants
1.6 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 4 COWS <5 (n=106,123)
99.1 Percentage of participants
100 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 4 COWS 5-12 (n=106,123)
0.9 Percentage of participants
0 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 8 COWS <5 (n=87,107)
100 Percentage of participants
98.1 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 8 COWS 5-12 (n=87,107)
0 Percentage of participants
1.9 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 12/ET COWS <5 (n=126,140)
98.4 Percentage of participants
97.9 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 12/ET COWS 5-12 (n=126,140)
0.8 Percentage of participants
2.1 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 12/ET COWS 13-24 (n=126,140)
0.8 Percentage of participants
0 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Max. DBP Value COWS <5 (n=126,140)
97.6 Percentage of participants
95.0 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Randomization Baseline COWS <5 (n=134,146)
100 Percentage of participants
100 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 1 COWS <5 (n=111,133)
99.1 Percentage of participants
98.5 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 1 COWS 5-12 (n=111,133)
0 Percentage of participants
1.5 Percentage of participants
Percentage of Participants With Opiate Withdrawal During the Double-Blind Treatment Period by COWS Category
Week 1 COWS 13-24 (n=111,133)
0.9 Percentage of participants
0 Percentage of participants

SECONDARY outcome

Timeframe: Follow-Up Weeks 1 and 2

Population: Double-Blind Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The COWS contains 11 common opiate withdrawal signs or symptoms rated by the investigator or designee who, for each item, checked the number that best described the participant's signs or symptoms. The minimum total COWS score is 0, the maximum is 48. The summed score of the 11 items was used to assess a participant's level of opiate withdrawal. The scores are assessed as follows: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=94 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=108 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Opiate Withdrawal During Post-Treatment by COWS Category
FU Week 1 COWS <5 (n=68,83)
100.0 Percentage of participants
100.0 Percentage of participants
Percentage of Participants With Opiate Withdrawal During Post-Treatment by COWS Category
FU Week 2 COWS <5 (n=78,91)
100 Percentage of participants
95.6 Percentage of participants
Percentage of Participants With Opiate Withdrawal During Post-Treatment by COWS Category
FU Week 2 COWS=5-12 (n=78,91)
0 Percentage of participants
4.4 Percentage of participants
Percentage of Participants With Opiate Withdrawal During Post-Treatment by COWS Category
Maximum FU Period COWS <5 (n=94,108)
100.0 Percentage of participants
96.3 Percentage of participants
Percentage of Participants With Opiate Withdrawal During Post-Treatment by COWS Category
Maximum FU Period COWS=5-12 (n=94,108)
0 Percentage of participants
3.7 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Weeks 1, 2, 3, 4, 5, and 6

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The SOWS was completed daily by the participant during any of the 2-week tapers from study drug, as well as at each study visit, using an eDiary device, and contains 16 symptoms of opiate withdrawal rated by the participant (Scale of 0 to 4: 0 = not at all, 1 = a little, 2= moderately, 3= quite a bit, 4 = extremely). The sum of the scores on each item was the total SOWS score; the minimum possible SOWS score was 0, the maximum 64. Higher scores indicate a worse outcome.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Screening (n=395)
4.1 Units on a scale
Standard Deviation 4.92
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Week 1 (n=355)
3.5 Units on a scale
Standard Deviation 4.31
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Change from Screening at Week 1 (n=346)
-0.7 Units on a scale
Standard Deviation 4.71
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Week 2 (n=329)
3.0 Units on a scale
Standard Deviation 3.66
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Change from Screening at Week 2 (n=320)
-1.2 Units on a scale
Standard Deviation 4.64
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Week 3 (n=311)
2.7 Units on a scale
Standard Deviation 4.17
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Change from Screening at Week 3 (n=304)
-1.4 Units on a scale
Standard Deviation 5.24
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Week 4 (n=206)
2.2 Units on a scale
Standard Deviation 2.92
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Change from Screening at Week 4 (n=199)
-2.1 Units on a scale
Standard Deviation 4.92
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Week 5 (n=139)
2.2 Units on a scale
Standard Deviation 2.96
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Change from Screening at Week 5 (n=133)
-2.4 Units on a scale
Standard Deviation 4.42
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Week 6/ET (n=369)
3.0 Units on a scale
Standard Deviation 4.41
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Change from Screening at Week 6/ET (n=359)
-1.2 Units on a scale
Standard Deviation 5.36
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Max. SOWS (Titration Period) (n=369)
4.9 Units on a scale
Standard Deviation 5.35
Subjective Opiate Withdrawal Scale (SOWS) During the Open-Label Titration Period
Change from Screening at Max. SOWS (n=359)
0.7 Units on a scale
Standard Deviation 5.51

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 1, 2, 4, 8, and 12

Population: Double-Blind Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The SOWS was completed daily by the participant during any of the 2-week tapers from study drug, as well as at each study visit, using an eDiary device, and contains 16 symptoms of opiate withdrawal rated by the participant (Scale of 0 to 4: 0 = not at all, 1 = a little, 2= moderately, 3= quite a bit, 4 = extremely). The sum of the scores on each item was the total SOWS score; the minimum possible SOWS score was 0, the maximum 64. Higher scores indicate a worse outcome.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
SOWS Total Score During the Double-Blind Treatment Period
Randomization Baseline (n=134,146)
2.4 Units on a scale
Standard Deviation 3.88
1.5 Units on a scale
Standard Deviation 2.20
SOWS Total Score During the Double-Blind Treatment Period
Week 1 (n=134,143)
3.0 Units on a scale
Standard Deviation 4.27
2.3 Units on a scale
Standard Deviation 3.69
SOWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 1 (n=134,143)
0.6 Units on a scale
Standard Deviation 4.08
0.8 Units on a scale
Standard Deviation 2.93
SOWS Total Score During the Double-Blind Treatment Period
Week 2 (n=123,135)
3.5 Units on a scale
Standard Deviation 6.56
1.9 Units on a scale
Standard Deviation 3.11
SOWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 2 (n=123,135)
1.1 Units on a scale
Standard Deviation 5.37
0.3 Units on a scale
Standard Deviation 2.64
SOWS Total Score During the Double-Blind Treatment Period
Max. SOWS, First 2 Weeks of Period (n=134,143)
6.3 Units on a scale
Standard Deviation 7.72
4.4 Units on a scale
Standard Deviation 5.11
SOWS Total Score During the Double-Blind Treatment Period
Week 4 (n=105,122)
2.5 Units on a scale
Standard Deviation 3.91
2.1 Units on a scale
Standard Deviation 3.42
SOWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 4 (n=105,122)
0.1 Units on a scale
Standard Deviation 3.57
0.5 Units on a scale
Standard Deviation 2.39
SOWS Total Score During the Double-Blind Treatment Period
Week 8 (n=85,110)
2.4 Units on a scale
Standard Deviation 4.48
2.1 Units on a scale
Standard Deviation 3.37
SOWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 8 (n=85,110)
0.1 Units on a scale
Standard Deviation 3.83
0.6 Units on a scale
Standard Deviation 2.92
SOWS Total Score During the Double-Blind Treatment Period
Week 12 (n=134,143)
3.3 Units on a scale
Standard Deviation 5.70
2.4 Units on a scale
Standard Deviation 3.85
SOWS Total Score During the Double-Blind Treatment Period
Change from Baseline at Week 12 (n=134,143)
0.9 Units on a scale
Standard Deviation 5.11
0.9 Units on a scale
Standard Deviation 3.01
SOWS Total Score During the Double-Blind Treatment Period
Max. SOWS (Double-Blind Period) (n=134,143)
6.7 Units on a scale
Standard Deviation 7.77
5.2 Units on a scale
Standard Deviation 5.89
SOWS Total Score During the Double-Blind Treatment Period
Change from Baseline at max. SOWs (n=134,143)
4.3 Units on a scale
Standard Deviation 5.82
3.7 Units on a scale
Standard Deviation 5.14

SECONDARY outcome

Timeframe: Follow-Up Weeks 1 and 2

Population: Double-Blind Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The SOWS was completed daily by the participant during any of the 2-week tapers from study drug, as well as at each study visit, using an eDiary device, and contains 16 symptoms of opiate withdrawal rated by the participant (Scale of 0 to 4: 0 = not at all, 1 = a little, 2= moderately, 3= quite a bit, 4 = extremely). The sum of the scores on each item was the total SOWS score; the minimum possible SOWS score was 0, the maximum 64. Higher scores indicate a worse outcome.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=96 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=110 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
SOWS Total Score During the Post-Treatment Period
FU Week 1 (n=94,108)
2.6 Units on a scale
Standard Deviation 4.91
2.3 Units on a scale
Standard Deviation 3.69
SOWS Total Score During the Post-Treatment Period
Change from Baseline at FU Week 1 (n=94,108)
0.2 Units on a scale
Standard Deviation 4.12
0.8 Units on a scale
Standard Deviation 3.21
SOWS Total Score During the Post-Treatment Period
FU Week 2 (n=95,109)
2.7 Units on a scale
Standard Deviation 5.26
2.5 Units on a scale
Standard Deviation 3.67
SOWS Total Score During the Post-Treatment Period
Change from Baseline at FU Week 2 (n=95,109)
0.2 Units on a scale
Standard Deviation 4.49
1.0 Units on a scale
Standard Deviation 3.35
SOWS Total Score During the Post-Treatment Period
Max. SOWS (FU Period)(n=96,110)
4.7 Units on a scale
Standard Deviation 6.73
4.5 Units on a scale
Standard Deviation 5.45
SOWS Total Score During the Post-Treatment Period
Change from Baseline at Max. SOWS, (n=96,110)
2.2 Units on a scale
Standard Deviation 5.31
3.0 Units on a scale
Standard Deviation 4.77

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

RMDQ is a 24-item questionnaire designed to measure self-rated disability due to back pain the same day the questionnaire is completed. An individual participant's score could have ranged from 0 (no disability) to 24 (severe disability), with a lower score indicating better function; higher scores indicating greater disability.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Open-Label Titration Period in Roland-Morris Disability Questionnaire (RMDQ) Total Score for All Participants
Screening (n=405)
12.7 Units on a scale
Standard Deviation 5.42
Change From Screening Period to End of Open-Label Titration Period in Roland-Morris Disability Questionnaire (RMDQ) Total Score for All Participants
End of Open-Label Titration Period (n=345)
9.0 Units on a scale
Standard Deviation 5.62
Change From Screening Period to End of Open-Label Titration Period in Roland-Morris Disability Questionnaire (RMDQ) Total Score for All Participants
Change from Screening (n=343)
-3.9 Units on a scale
Standard Deviation 4.91

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

RMDQ is a 24-item questionnaire designed to measure self-rated disability due to back pain the same day the questionnaire is completed. An individual participant's score could have ranged from 0 (no disability) to 24 (severe disability), with a lower score indicating better function.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to Randomization Baseline in RMDQ Total Score
Screening (n=277)
12.8 Units on a scale
Standard Deviation 5.22
Change From Screening Period to Randomization Baseline in RMDQ Total Score
Randomization Baseline (n=256)
7.9 Units on a scale
Standard Deviation 5.14
Change From Screening Period to Randomization Baseline in RMDQ Total Score
Change from Screening (n=255)
-4.8 Units on a scale
Standard Deviation 4.95

SECONDARY outcome

Timeframe: Screening, Weeks 2, 4, 8, and 12

Population: ITT Population; imputation using the LOCF method for Week 12 only; Weeks 2, 4, 8 included observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

RMDQ is a 24-item questionnaire designed to measure self-rated disability due to back pain the same day the questionnaire is completed. An individual participant's score could have ranged from 0 (no disability) to 24 (severe disability), with a lower score indicating better function.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in RMDQ Total Score
Week 2 (n=114,124)
-3.88 Units on a scale
Standard Error 0.423
-4.93 Units on a scale
Standard Error 0.406
Change From Screening Period to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in RMDQ Total Score
Week 4 (n=101,111)
-3.90 Units on a scale
Standard Error 0.467
-4.60 Units on a scale
Standard Error 0.444
Change From Screening Period to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in RMDQ Total Score
Week 8 (n=77,95)
-4.50 Units on a scale
Standard Error 0.514
-3.92 Units on a scale
Standard Error 0.459
Change From Screening Period to End of Double-Blind Weeks 2, 4, 8, and 12 (or Final Visit) in RMDQ Total Score
Week 12/ET (n=123,128)
-4.33 Units on a scale
Standard Error 0.440
-4.26 Units on a scale
Standard Error 0.431

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 2, 4, and 8

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

RMDQ is a 24-item questionnaire designed to measure self-rated disability due to back pain the same day the questionnaire is completed. An individual participant's score could have ranged from 0 (no disability) to 24 (severe disability), with a lower score indicating better function.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to the End of Double-Blind Weeks 2, 4, and 8 in RMDQ Total Score
Week 2 (n=111,118)
0.54 Units on a scale
Standard Error 0.334
-0.19 Units on a scale
Standard Error 0.321
Change From Randomization Baseline to the End of Double-Blind Weeks 2, 4, and 8 in RMDQ Total Score
Week 4 (n=98,107)
1.02 Units on a scale
Standard Error 0.420
0.32 Units on a scale
Standard Error 0.397
Change From Randomization Baseline to the End of Double-Blind Weeks 2, 4, and 8 in RMDQ Total Score
Week 8 (n=73,93)
-0.01 Units on a scale
Standard Error 0.471
0.41 Units on a scale
Standard Error 0.408

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; percentage was based on the number of participants who had non-missing values at Randomization Baseline and Screening.

Represents the score at Screening / score at Randomization Baseline in PGA of low back pain, a global evaluation that utilizes a 5-point Likert scale with a score of: 1 = very good, asymptomatic and no limitation of normal activities; 2 = good, mild symptoms, and no limitation of normal activities; 3 = fair, moderate symptoms and limitation to some normal activities; 4 = poor, severe symptoms and inability to carry out most normal activities; and a score of 5 = very poor; very severe symptoms, which were intolerable and inability to carry out all normal activities.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=277 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Very Good
0.4 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Good
2.9 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Fair
9.4 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Poor
2.9 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Very Poor
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Good
5.8 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Fair
29.2 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Poor
8.7 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Very Poor
1.4 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Good
2.5 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Fair
22.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Poor
10.5 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Very Poor
1.4 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Good
0.4 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Fair
2.2 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Poor
0.4 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Very Poor
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Fair
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Poor
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to Randomization Baseline in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Very Poor
0.0 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Randomization Baseline, or Early Termination

Population: Titration Period Safety Population; percentage was based on the number of participants who had non-missing values at Randomization Baseline and Screening.

Represents the score at Screening / score at to end of the titration period in PGA of low back pain, a global evaluation that utilizes a 5-point Likert scale with a score of: 1 = very good, asymptomatic and no limitation of normal activities; 2 = good, mild symptoms, and no limitation of normal activities; 3 = fair, moderate symptoms and limitation to some normal activities; 4 = poor, severe symptoms and inability to carry out most normal activities; and a score of 5 = very poor; very severe symptoms, which were intolerable and inability to carry out all normal activities.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=368 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Fair
27.2 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Poor
10.6 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Very Poor
1.4 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Good
0.3 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Fair
3.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Poor
2.2 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Very Poor
0.3 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Fair
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Poor
0.3 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Very Poor
0.3 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Very Good
0.3 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Good
2.7 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Fair
7.6 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Poor
2.2 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Very Poor
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Good
5.4 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Fair
25.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Poor
7.6 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Very Poor
1.1 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Very Good
0.0 Percentage of participants
Percentage of Participants With Shift From Screening to the End of the Open-Label Titration Period in PGA of Low Back Pain by Category in Participants With Screening PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Good
2.7 Percentage of participants

SECONDARY outcome

Timeframe: Randomization Baseline, Week 4

Population: ITT Population; percentage was based on the number of participants who had non-missing values at Randomization Baseline and Week 4 for each treatment.

Represents the score at Randomization Baseline / score at Week 4 in PGA of low back pain, a global evaluation that utilizes a 5-point Likert scale with a score of: 1 = very good, asymptomatic and no limitation of normal activities; 2 = good, mild symptoms, and no limitation of normal activities; 3 = fair, moderate symptoms and limitation to some normal activities; 4 = poor, severe symptoms and inability to carry out most normal activities; and a score of 5 = very poor; very severe symptoms, which were intolerable and inability to carry out all normal activities.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=109 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=126 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Good
15.6 Percentage of participants
15.1 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Very Good
0.9 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Very Good
7.3 Percentage of participants
8.7 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Fair
24.8 Percentage of participants
23.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Poor
1.8 Percentage of participants
2.4 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Good
2.8 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Good
3.7 Percentage of participants
0.8 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Fair
0.9 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Good / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Very Good
5.5 Percentage of participants
6.3 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Good
24.8 Percentage of participants
27.8 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Fair
7.3 Percentage of participants
13.5 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Good / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Fair / Very Good
0.9 Percentage of participants
1.6 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Fair
2.8 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Poor
0.0 Percentage of participants
0.8 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Poor / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Very Good
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Good
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Fair
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Poor
0.9 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 4 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good, Good, Fair, Poor, Very Poor
Very Poor / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants

SECONDARY outcome

Timeframe: Randomization Baseline, Week 8

Population: ITT Population; percentage was based on the number of participants who had non-missing values at Randomization Baseline and Week 8 for each treatment.

Represents the score at Randomization Baseline / score at Week 8 in PGA of low back pain, a global evaluation that utilizes a 5-point Likert scale with a score of: 1 = very good, asymptomatic and no limitation of normal activities; 2 = good, mild symptoms, and no limitation of normal activities; 3 = fair, moderate symptoms and limitation to some normal activities; 4 = poor, severe symptoms and inability to carry out most normal activities; and a score of 5 = very poor; very severe symptoms, which were intolerable and inability to carry out all normal activities.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=88 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=112 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Good / Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Good / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Good / Very Good
8.0 Percentage of participants
8.9 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Good / Good
5.7 Percentage of participants
3.6 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Good / Fair
0.0 Percentage of participants
1.8 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Good / Very Good
5.7 Percentage of participants
8.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Good / Good
25.0 Percentage of participants
23.2 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Good / Fair
12.5 Percentage of participants
11.6 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Good / Poor
0.0 Percentage of participants
0.9 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Good / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Fair / Very Good
3.4 Percentage of participants
0.9 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Fair / Good
14.8 Percentage of participants
15.2 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Fair / Fair
17.0 Percentage of participants
21.4 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Fair / Poor
2.3 Percentage of participants
1.8 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Fair / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Poor / Very Good
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Poor / Good
1.1 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Poor / Fair
1.1 Percentage of participants
0.9 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Poor / Poor
0.0 Percentage of participants
0.9 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Poor / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Poor / Very Good
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Poor / Good
0.0 Percentage of participants
0.9 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Poor / Fair
2.3 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Poor / Poor
1.1 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Week 8 in PGA of Low Back Pain by Category in Participants With Randomization Baseline PGA Score of Very Good , Good, Fair, Poor, Very Poor
Very Poor / Very Poor
0.0 Percentage of participants
0.0 Percentage of participants

SECONDARY outcome

Timeframe: End of Open-Label Titration Period (Week 4, 5, or 6 or Early Termination)

Population: Titration Period Safety Population; percentage was based on the number of participants with non-missing response to treatment. n=number of participants analyzed for the given parameter at the specified timepoint.

Satisfaction with treatment is a single-item self-rated instrument that measures the participant's overall satisfaction with the study drug during study participation on a 5-point likert scale ranging from 1 = Very dissatisfied to 5 = Very satisfied.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=369 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Satisfaction With Treatment at the End of Open-Label Titration Period for All Participants
Very Satisfied (n=369)
33.9 Percentage of participants
Satisfaction With Treatment at the End of Open-Label Titration Period for All Participants
Very Dissatisfied (n=369)
6.8 Percentage of participants
Satisfaction With Treatment at the End of Open-Label Titration Period for All Participants
Dissatisfied (n=369)
7.0 Percentage of participants
Satisfaction With Treatment at the End of Open-Label Titration Period for All Participants
Neither Satisfied or Dissatisfied (n=369)
11.7 Percentage of participants
Satisfaction With Treatment at the End of Open-Label Titration Period for All Participants
Satisfied (n=369)
40.7 Percentage of participants

SECONDARY outcome

Timeframe: Randomization Baseline

Population: ITT Population; percentage was based on the number of participants with non-missing response to treatment. n=number of participants analyzed for the given parameter at the specified timepoint.

Satisfaction with treatment is a single-item self-rated instrument that measures the participant's overall satisfaction with the study drug during study participation on a 5-point likert scale ranging from 1 = Very dissatisfied to 5 = Very satisfied.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=278 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Satisfaction With Treatment at Randomization Baseline
Very Dissatisfied (n=278)
5.4 Percentage of participants
Satisfaction With Treatment at Randomization Baseline
Dissatisfied (n=278)
2.2 Percentage of participants
Satisfaction With Treatment at Randomization Baseline
Neither Satisfied or Dissatisfied (n=278)
4.7 Percentage of participants
Satisfaction With Treatment at Randomization Baseline
Satisfied (n=278)
46.0 Percentage of participants
Satisfaction With Treatment at Randomization Baseline
Very Satisfied (n=278)
41.7 Percentage of participants

SECONDARY outcome

Timeframe: Week 12 or Early Termination

Population: ITT Population; percentage was based on the number of participants with non-missing response to treatment. n=number of participants analyzed for the given parameter at the specified timepoint.

Participants used an electronic tablet at the center to rate their overall treatment satisfaction with study drug during study participation using a 5-point categorical scale (1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = very satisfied).

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=125 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=128 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants Who Reported Being Satisfied/Very Satisfied With Treatment on the Satisfaction With Treatment Questionnaire During the Double-Blind Treatment Period
Yes (n=125,128)
59.2 Percentage of participants
79.7 Percentage of participants
Percentage of Participants Who Reported Being Satisfied/Very Satisfied With Treatment on the Satisfaction With Treatment Questionnaire During the Double-Blind Treatment Period
No (n=125,128)
40.8 Percentage of participants
20.3 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

SF-36v2 Health Survey is a self-administered questionnaire consisting of 36 questions, measuring 8 health aspects; physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. These domains also combine to form two component summary scores evaluating mental health and physical health. The minimum score is 0 and the maximum score is 100. A higher scores indicates a better health state.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
General Health (n=367)
2.3 Score on a scale
Standard Deviation 6.54
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Physical Functioning (n=366)
6.7 Score on a scale
Standard Deviation 8.96
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Role-Physical (n=366)
7.7 Score on a scale
Standard Deviation 9.48
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Bodily Pain (n=366)
9.8 Score on a scale
Standard Deviation 8.44
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Vitality (n=366)
4.6 Score on a scale
Standard Deviation 8.98
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Social Functioning (n=367)
5.0 Score on a scale
Standard Deviation 11.01
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Role-Emotional (n=367)
3.4 Score on a scale
Standard Deviation 12.19
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Mental Health (n=367)
2.3 Score on a scale
Standard Deviation 8.76
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Physical Component Score (n=364)
8.2 Score on a scale
Standard Deviation 7.90
Change From Screening Period to the End of Open-Label Titration Period in Short Form-36v2 (SF-36v2) Health Survey Score
Mental Component Score (n=364)
1.6 Score on a scale
Standard Deviation 10.05

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

SF-36v2 Health Survey is a self-administered questionnaire consisting of 36 questions, measuring 8 health aspects; physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. These domains also combine to form two component summary scores evaluating mental health and physical health. The minimum score is 0 and the maximum score is 100. A higher score indicate a better health state.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Physical Functioning (n=276)
8.0 Score on a scale
Standard Deviation 8.90
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Role-Physical (n=276)
9.1 Score on a scale
Standard Deviation 9.40
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Bodily Pain (n=276)
11.6 Score on a scale
Standard Deviation 7.91
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
General Health (n=277)
3.1 Score on a scale
Standard Deviation 6.65
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Vitality (n=276)
5.8 Score on a scale
Standard Deviation 9.08
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Social Functioning (n=277)
7.0 Score on a scale
Standard Deviation 10.27
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Role-Emotional (n=277)
4.7 Score on a scale
Standard Deviation 12.04
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Mental Health (n=277)
3.5 Score on a scale
Standard Deviation 8.29
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Physical Component Score (n=274)
9.6 Score on a scale
Standard Deviation 7.77
Change From Screening Period to Randomization Baseline in SF-36v2 Health Survey Score
Mental Component Score (n=274)
2.9 Score on a scale
Standard Deviation 9.69

SECONDARY outcome

Timeframe: Randomization Baseline, Week 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

SF-36v2 Health Survey is a self-administered questionnaire consisting of 36 questions, measuring 8 health aspects; physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. These domains also combine to form two component summary scores evaluating mental health and physical health. The minimum score is 0 and the maximum score is 100. A higher score indicate a better health state.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Physical Functioning (n=122,125)
-2.06 Score on a scale
Standard Error 0.681
-1.44 Score on a scale
Standard Error 0.666
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Role-Physical (n=124,126)
-2.56 Score on a scale
Standard Error 0.713
-2.59 Score on a scale
Standard Error 0.701
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Bodily Pain (n=124,127)
-5.07 Score on a scale
Standard Error 0.655
-2.69 Score on a scale
Standard Error 0.643
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
General Health Perceptions (n=124,126)
-1.55 Score on a scale
Standard Error 0.545
-2.10 Score on a scale
Standard Error 0.536
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Vitality (n=123,127)
-1.62 Score on a scale
Standard Error 0.781
-2.77 Score on a scale
Standard Error 0.762
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Social Functioning (n=124,127)
-3.17 Score on a scale
Standard Error 0.748
-1.69 Score on a scale
Standard Error 0.734
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Role-Emotional (n=124,127)
-2.57 Score on a scale
Standard Error 0.963
-3.44 Score on a scale
Standard Error 0.943
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Mental Health (n=124,127)
-2.95 Score on a scale
Standard Error 0.711
-2.93 Score on a scale
Standard Error 0.697
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Physical Component Score (n=121,125)
-2.70 Score on a scale
Standard Error 0.635
-1.68 Score on a scale
Standard Error 0.620
Change From Randomization Baseline to the End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Mental Component Score (n=121,125)
-2.29 Score on a scale
Standard Error 0.767
-2.98 Score on a scale
Standard Error 0.749

SECONDARY outcome

Timeframe: Screening, Week 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

SF-36v2 Health Survey is a self-administered questionnaire consisting of 36 questions, measuring 8 health aspects; physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. These domains also combine to form two component summary scores evaluating mental health and physical health. The minimum score is 0 and the maximum score is 100. A higher score indicate a better health state.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Physical Functioning (n=123,126)
5.32 Score on a scale
Standard Error 0.794
6.84 Score on a scale
Standard Error 0.787
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Role-Physical (n=125,127)
5.68 Score on a scale
Standard Error 0.805
6.78 Score on a scale
Standard Error 0.802
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Bodily Pain (n=125,127)
6.39 Score on a scale
Standard Error 0.747
8.78 Score on a scale
Standard Error 0.743
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
General Health Perceptions (n=125,126)
1.28 Score on a scale
Standard Error 0.611
1.07 Score on a scale
Standard Error 0.609
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Vitality (n=125,127)
3.46 Score on a scale
Standard Error 0.798
3.01 Score on a scale
Standard Error 0.794
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Social Functioning (n=125,127)
3.58 Score on a scale
Standard Error 0.771
5.57 Score on a scale
Standard Error 0.768
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Role-Emotional (n=125,127)
0.99 Score on a scale
Standard Error 0.979
1.22 Score on a scale
Standard Error 0.975
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Mental Health (n=125,127)
0.09 Score on a scale
Standard Error 0.752
0.47 Score on a scale
Standard Error 0.748
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Physical Component Score (n=123,126)
6.42 Score on a scale
Standard Error 0.721
8.09 Score on a scale
Standard Error 0.715
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in SF-36v2 Health Survey
Mental Component Score (n=123,126)
-0.44 Score on a scale
Standard Error 0.816
-0.45 Score on a scale
Standard Error 0.808

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The EQ 5D Health Questionnaire is a self completion standardized instrument for use as a measure of health-related quality of life in terms of a single index value or utility score that consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which was rated on a 3-point response scale (no problems/some or moderate problems/extreme problems), and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EuroQol 5-Dimensions (EQ-5D) Summary Index
Screening (n=400)
0.68 Score on a scale
Standard Deviation 0.174
Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EuroQol 5-Dimensions (EQ-5D) Summary Index
End of Open-Label (n=354)
0.80 Score on a scale
Standard Deviation 0.134
Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EuroQol 5-Dimensions (EQ-5D) Summary Index
Change from Screening (n=346)
0.12 Score on a scale
Standard Deviation 0.174

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The EQ-5D consists of a standard vertical 20cm visual analogue scale (EQ VAS), for recording a participant's rating for their current health related quality of life state; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). Participants were asked to draw a line on the scale to indicate how good or bad your own health is today, in your opinion.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EQ-5D VAS
Screening (n=406)
66.23 Score on a scale
Standard Deviation 18.277
Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EQ-5D VAS
End of Open-Label (n=367)
74.69 Score on a scale
Standard Deviation 18.204
Change From Screening Period to the End of Open-Label Titration Period in Participant Assessment of Overall Health State Using the EQ-5D VAS
Change from Screening (n=364)
8.16 Score on a scale
Standard Deviation 19.398

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Self-completion standardized instrument for use as a measure of health-related quality of life in terms of a single index value or utility score that consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which was rated on a 3-point response scale (no problems/some or moderate problems/extreme problems), and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D Summary Index
Screening (n=272)
0.68 Score on a scale
Standard Deviation 0.178
Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D Summary Index
Randomization Baseline (n=267)
0.82 Score on a scale
Standard Deviation 0.120
Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D Summary Index
Change from Screening (n=260)
0.14 Score on a scale
Standard Deviation 0.177

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The EQ-5D consists of a standard vertical 20cm visual analogue scale (EQ VAS), for recording a participant's rating for their current health related quality of life state; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). Participants were asked to draw a line on the scale to indicate how good or bad your own health is today, in your opinion.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D VAS
Screening (n=279)
67.02 Score on a scale
Standard Deviation 18.518
Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D VAS
Randomization Baseline (n=276)
76.85 Score on a scale
Standard Deviation 17.407
Change From Screening Period to Randomization Baseline in Participant Assessment of Overall Health State Using the EQ-5D VAS
Change from Screening (n=275)
9.84 Score on a scale
Standard Deviation 19.692

SECONDARY outcome

Timeframe: Randomization Baseline, Week 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Self-completion standardized instrument for use as a measure of health-related quality of life in terms of a single index value or utility score that consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which was rated on a 3-point response scale (no problems/some or moderate problems/extreme problems), and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=118 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=115 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using EQ-5D Summary Index
-0.061 Score on a scale
Standard Error 0.0118
-0.029 Score on a scale
Standard Error 0.0120

SECONDARY outcome

Timeframe: Randomization Baseline, Week 12

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

The EQ-5D consists of a standard vertical 20cm visual analogue scale (EQ VAS), for recording a participant's rating for their current health related quality of life state; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). Participants were asked to draw a line on the scale to indicate how good or bad your own health is today, in your opinion.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=122 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=126 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using the EQ-5D VAS
-3.61 Score on a scale
Standard Error 1.432
-2.89 Score on a scale
Standard Error 1.401

SECONDARY outcome

Timeframe: Screening, Week 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Self-completion standardized instrument for use as a measure of health-related quality of life in terms of a single index value or utility score that consisted of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which was rated on a 3-point response scale (no problems/some or moderate problems/extreme problems), and the scores are combined to form a single index utility value between 0 and 1 with higher scores indicating better health.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=121 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=117 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using EQ-5D Summary Index
0.085 Score on a scale
Standard Error 0.0121
0.106 Score on a scale
Standard Error 0.0124

SECONDARY outcome

Timeframe: Screening, Week 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

The EQ-5D consists of a standard vertical 20cm visual analogue scale (EQ VAS), for recording a participant's rating for their current health related quality of life state; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). Participants were asked to draw a line on the scale to indicate how good or bad your own health is today, in your opinion.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=124 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=127 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Week 12 (or Final Visit) in Participant Assessment of Overall Health State Using EQ-5D VAS
4.75 Score on a scale
Standard Error 1.465
7.01 Score on a scale
Standard Error 1.454

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment /absenteeism+presenteeism); and activity impairment. * work time missed - a measure of absenteeism, calculated as work time missed due to health problem (question 2) as a proportion of hours actually worked (question 4). * impairment while working - a measure of presenteeism, the degree to which health problem impacted work (question 5). * overall work impairment - a measure of overall work productivity loss due to health problem (absenteeism+presenteeism). * activity impairment - a measure of the degree to which health problem has affected ability to do regular activities other than work at a job (question 6). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Open-Label in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP): % Work Time Missed, % Impairment, % Overall Work Impairment, % Activity Impairment Due to Low Back Pain
Percent Work Time Missed (n=119)
-1.3 Percentage
Standard Deviation 16.66
Change From Screening Period to End of Open-Label in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP): % Work Time Missed, % Impairment, % Overall Work Impairment, % Activity Impairment Due to Low Back Pain
Percent Impairment While Working (n=112)
-22.4 Percentage
Standard Deviation 26.95
Change From Screening Period to End of Open-Label in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP): % Work Time Missed, % Impairment, % Overall Work Impairment, % Activity Impairment Due to Low Back Pain
Percent Overall Work Impairment (n=110)
-21.6 Percentage
Standard Deviation 29.83
Change From Screening Period to End of Open-Label in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP): % Work Time Missed, % Impairment, % Overall Work Impairment, % Activity Impairment Due to Low Back Pain
Percent Activity Impairment (n=363)
-27.2 Percentage
Standard Deviation 24.45

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. * work time missed - a measure of absenteeism, calculated as work time missed due to health problem (question 2) as a proportion of hours actually worked (question 4). * impairment while working - a measure of presenteeism, the degree to which health problem impacted work (question 5). * overall work impairment - a measure of overall work productivity loss due to health problem (absenteeism+presenteeism). * activity impairment - a measure of the degree to which health problem has affected ability to do regular activities other than work at a job (question 6). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to Randomization Baseline in WPAI:SHP: Percent Work Time Missed, Percent Impairment, Percent Overall Work Impairment, Percent Activity Impairment Due to Low Back Pain
Percent Work Time Missed (n=91)
-4.9 Percentage
Standard Deviation 14.37
Change From Screening Period to Randomization Baseline in WPAI:SHP: Percent Work Time Missed, Percent Impairment, Percent Overall Work Impairment, Percent Activity Impairment Due to Low Back Pain
Percent Impairment While Working (n=86)
-25.9 Percentage
Standard Deviation 27.24
Change From Screening Period to Randomization Baseline in WPAI:SHP: Percent Work Time Missed, Percent Impairment, Percent Overall Work Impairment, Percent Activity Impairment Due to Low Back Pain
Percent Overall Work Impairment (n=85)
-26.9 Percentage
Standard Deviation 27.76
Change From Screening Period to Randomization Baseline in WPAI:SHP: Percent Work Time Missed, Percent Impairment, Percent Overall Work Impairment, Percent Activity Impairment Due to Low Back Pain
Percent Activity Impairment (n=273)
-32.0 Percentage
Standard Deviation 23.96

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % work time missed - a measure of absenteeism, calculated as work time missed due to health problem (question 2) as a proportion of hours actually worked (question 4). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=44 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=56 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
Week 4 (n=36,44)
3.54 Percentage
Standard Error 2.213
-0.77 Percentage
Standard Error 1.906
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
Week 8 (n=25,41)
4.29 Percentage
Standard Error 3.507
1.41 Percentage
Standard Error 2.592
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
Week 12/ET (n=40,50)
6.49 Percentage
Standard Error 3.108
3.72 Percentage
Standard Error 2.675

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % impairment while working - a measure of presenteeism, the degree to which health problem impacted work (question 5). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=42 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=54 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
Week 4 (n=30,42)
5.22 Percentage
Standard Error 3.366
-1.54 Percentage
Standard Error 2.734
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
Week 8 (n=21,37)
3.63 Percentage
Standard Error 4.318
-1.36 Percentage
Standard Error 3.027
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
Week 12/ET (n=35,46)
6.77 Percentage
Standard Error 3.475
4.39 Percentage
Standard Error 2.918

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % overall work impairment - a measure of overall work productivity loss due to health problem (absenteeism+presenteeism). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=42 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=53 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
Week 4 (n=30,42)
5.31 Percentage
Standard Error 3.894
-2.03 Percentage
Standard Error 3.147
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
Week 8 (n=21,37)
8.69 Percentage
Standard Error 5.276
-0.66 Percentage
Standard Error 3.666
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
Week 12/ET (n=35,46)
10.85 Percentage
Standard Error 4.266
5.71 Percentage
Standard Error 3.575

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % activity impairment - a measure of the degree to which health problem has affected ability to do regular activities other than work at a job (question 6). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=131 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=144 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
Week 4 (n=108,125)
6.23 Percentage
Standard Error 1.768
1.98 Percentage
Standard Error 1.626
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
Week 8 (n=85,112)
2.05 Percentage
Standard Error 2.044
3.05 Percentage
Standard Error 1.752
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
Week 12/ET (n=128,135)
10.56 Percentage
Standard Error 1.818
6.41 Percentage
Standard Error 1.758

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % work time missed - a measure of absenteeism, calculated as work time missed due to health problem (question 2) as a proportion of hours actually worked (question 4). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=46 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=58 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
Week 4 (n=36,43)
-0.09 Percentage
Standard Error 2.147
-4.82 Percentage
Standard Error 1.911
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
Week 8 (n=24,40)
-1.42 Percentage
Standard Error 2.785
-3.01 Percentage
Standard Error 2.123
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Work Time Missed Due to Low Back Pain
Week 12/ET (n=40,49)
-1.00 Percentage
Standard Error 2.612
-2.09 Percentage
Standard Error 2.307

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % impairment while working - a measure of presenteeism, the degree to which health problem impacted work (question 5). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=47 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=56 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
Week 4 (n=33,42)
-18.65 Percentage
Standard Error 3.614
-31.03 Percentage
Standard Error 3.151
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
Week 8 (n=22,37)
-16.43 Percentage
Standard Error 4.374
-29.37 Percentage
Standard Error 3.263
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Impairment Due to Low Back Pain
Week 12/ET (n=38,46)
-16.18 Percentage
Standard Error 3.642
-25.38 Percentage
Standard Error 3.242

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % overall work impairment - a measure of overall work productivity loss due to health problem (absenteeism+presenteeism). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=46 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=56 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
Week 4 (n=32,41)
-19.84 Percentage
Standard Error 3.992
-32.40 Percentage
Standard Error 3.470
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
Week 8 (n=21,37)
-15.21 Percentage
Standard Error 4.933
-29.37 Percentage
Standard Error 3.608
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Overall Work Impairment Due to Low Back Pain
Week 12/ET (n=37,46)
-15.16 Percentage
Standard Error 4.268
-25.51 Percentage
Standard Error 3.759

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; imputation by the LOCF method was used for Week 12 (or Final Visit) only; Weeks 4 and 8 were based on observed cases. n=number of participants analyzed for the given parameter at the specified timepoint.

A self-reported measure of work productivity and impairment that yields 4 scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism+presenteeism); and activity impairment. % activity impairment - a measure of the degree to which health problem has affected ability to do regular activities other than work at a job (question 6). Each score is expressed as a percentage (0-100%) with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=133 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=145 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
Week 4 (n=109,125)
-23.75 Percentage
Standard Error 1.960
-31.24 Percentage
Standard Error 1.829
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
Week 8 (n=87,112)
-25.25 Percentage
Standard Error 2.279
-29.87 Percentage
Standard Error 2.005
Change From Screening Period to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in WPAI:SHP Percent Activity Impairment Due to Low Back Pain
Week 12/ET (n=130,136)
-18.62 Percentage
Standard Error 2.025
-26.81 Percentage
Standard Error 1.981

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; the denominator for the percentage calculation is the number of participants who had both Screening value and End of Open-Label value.

Question 3a = In the past 4 weeks, have you been hospitalized due to chronic low back pain or any medication used for chronic low back pain?

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=362 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Screening Period to End of Open-Label Titration Period in Hospitalization Because of Low Back Pain as Assessed Using the Healthcare Resource Use (HRU) Questionnaire
No/No
96.4 Percentage of participants
Percentage of Participants With Shift From Screening Period to End of Open-Label Titration Period in Hospitalization Because of Low Back Pain as Assessed Using the Healthcare Resource Use (HRU) Questionnaire
Yes/Yes
0.3 Percentage of participants
Percentage of Participants With Shift From Screening Period to End of Open-Label Titration Period in Hospitalization Because of Low Back Pain as Assessed Using the Healthcare Resource Use (HRU) Questionnaire
Yes/No
0.8 Percentage of participants
Percentage of Participants With Shift From Screening Period to End of Open-Label Titration Period in Hospitalization Because of Low Back Pain as Assessed Using the Healthcare Resource Use (HRU) Questionnaire
No/Yes
2.5 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; the denominator for the percentage calculation is the number of participants who had both Screening value and Randomization Baseline value.

Question 3a = In the past 4 weeks, have you been hospitalized due to chronic low back pain or any medication used for chronic low back pain?

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=272 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Screening Period to Randomization Baseline in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/Yes
0.4 Percentage of participants
Percentage of Participants With Shift From Screening Period to Randomization Baseline in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/No
1.1 Percentage of participants
Percentage of Participants With Shift From Screening Period to Randomization Baseline in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/Yes
2.9 Percentage of participants
Percentage of Participants With Shift From Screening Period to Randomization Baseline in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/No
95.6 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Question 1: number of office visits directly related to chronic low back pain or any medication used for chronic low back pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to Randomization Baseline in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
Screening (n=257)
11.4 Number of visits
Standard Deviation 38.97
Change From Screening to Randomization Baseline in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
Randomization Baseline (n=247)
5.6 Number of visits
Standard Deviation 21.84
Change From Screening to Randomization Baseline in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
Change from Screening (n=234)
-4.7 Number of visits
Standard Deviation 39.19

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Question 2: Money (dollars) spent out-of-pocket on physical treatments in the past 4 weeks to manage chronic low back pain

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to Randomization Baseline in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
Screening (n=264)
84.7 Dollars
Standard Deviation 418.06
Change From Screening to Randomization Baseline in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
Randomization Baseline (n=260)
51.8 Dollars
Standard Deviation 360.94
Change From Screening to Randomization Baseline in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
Change from Screening (n=248)
-41.8 Dollars
Standard Deviation 522.53

SECONDARY outcome

Timeframe: Screening, Randomization Baseline

Population: ITT Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Question 3b: nights stayed in the hospital, if answer to Q3a was yes.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=280 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to Randomization Baseline in HRU Questionnaire: Nights Stayed in Hospital
Screening (n=9)
0.1 Number of days
Standard Deviation 0.33
Change From Screening to Randomization Baseline in HRU Questionnaire: Nights Stayed in Hospital
Randomization Baseline (n=3)
0.0 Number of days
Standard Deviation 0.00
Change From Screening to Randomization Baseline in HRU Questionnaire: Nights Stayed in Hospital
Change from Screening (n=1)
0.0 Number of days
Standard Deviation NA
Standard Deviation not applicable as n=1

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Question 1: number of office visits directly related to chronic low back pain or any medication used for chronic low back pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
Screening (n=373)
8.8 Number of visits
Standard Deviation 33.07
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
Randomization Baseline (n=325)
5.4 Number of visits
Standard Deviation 20.58
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Number of Office Visits Directly Related or Any Medication Used for Chronic Low Back Pain
Change from Screening (n=308)
-3.0 Number of visits
Standard Deviation 35.29

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Question 2: Money (dollars) spent out-of-pocket on physical treatments in the past 4 weeks to manage chronic low back pain

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
Screening (n=388)
104.1 Dollars
Standard Deviation 605.48
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
Randomization Baseline (n=343)
88.0 Dollars
Standard Deviation 674.20
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Money Spent on Physical Treatments in Past 4 Weeks
Change from Screening (n=329)
-28.3 Dollars
Standard Deviation 548.03

SECONDARY outcome

Timeframe: Screening, Week 6 (or Early Termination)

Population: Titration Period Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Question 3b: nights stayed in the hospital, if answer to Q3a was yes.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Nights Stayed in Hospital
Screening (n=9)
0.1 Number of days
Standard Deviation 0.33
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Nights Stayed in Hospital
Randomization Baseline (n=3)
0.0 Number of days
Standard Deviation 0.00
Change From Screening to End of Open-Label Titration Period in HRU Questionnaire: Nights Stayed in Hospital
Change from Screening (n=1)
0.0 Number of days
Standard Deviation NA
Standard Deviation not applicable as n=1

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12 (or Early Termination)

Population: ITT Population; the denominator for the percentage calculation is the number of participants who had both Randomization Baseline value and Post Randomization value for each treatment and visit. Imputation using the LOCF method.

Question 3a = In the past 4 weeks, have you been hospitalized due to chronic low back pain or any medication used for chronic low back pain?

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/Yes Week 4 (n=108, 123)
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/No Week 4 (n=108, 123)
3.7 Percentage of participants
0.8 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/Yes Week 4 (n=108, 123)
1.9 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/No Week 4 (n=108, 123)
94.4 Percentage of participants
99.2 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/Yes Week 8 (n=85, 110)
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/No Week 8 (n=85, 110)
1.2 Percentage of participants
0.9 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/Yes Week 8 (n=85, 110)
2.4 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/No Week 8 (n=85, 110)
96.5 Percentage of participants
99.1 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/Yes Week12/ET (n=129, 134)
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/No Week12/ET (n=129, 134)
3.1 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/Yes Week12/ET (n=129, 134)
1.6 Percentage of participants
0.7 Percentage of participants
Percentage of Participants With Shift From Randomization Baseline to End of Double-Blind Weeks 4, 8, and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/No Week 12/ET (n=129, 134)
95.3 Percentage of participants
99.3 Percentage of participants

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Question 1: number of office visits directly related to chronic low back pain or any medication used for chronic low back pain

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
Randomization Baseline (n=118,129)
4.4 Number of visits
Standard Deviation 18.10
6.6 Number of visits
Standard Deviation 24.80
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
Week 4 (n=100,110)
6.5 Number of visits
Standard Deviation 24.35
5.3 Number of visits
Standard Deviation 37.99
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
Change from Baseline at Week 4 (n=95,106)
0.1 Number of visits
Standard Deviation 24.17
-3.1 Number of visits
Standard Deviation 46.85
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
Week 8 (n=79,103)
22.8 Number of visits
Standard Deviation 179.55
3.3 Number of visits
Standard Deviation 13.46
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
Change from Baseline at Week 8 (n=74,100)
-1.2 Number of visits
Standard Deviation 20.35
-2.6 Number of visits
Standard Deviation 24.31
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
Week 12/ET (n=121,128)
19.2 Number of visits
Standard Deviation 153.80
4.2 Number of visits
Standard Deviation 15.38
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related to or Medications Used for Chronic Low Back Pain
Change from Baseline at Week 12/ET (n=112,119)
-0.3 Number of visits
Standard Deviation 24.90
-4.1 Number of visits
Standard Deviation 27.74

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12

Population: ITT Population, imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Question 2: money (dollars) spent out-of-pocket on physical treatments in the past 4 weeks to manage chronic low back pain.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
Randomization Baseline (n=124,136)
96.4 Dollars
Standard Deviation 518.89
11.3 Dollars
Standard Deviation 33.77
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
Week 4 (n=104,119)
19.9 Dollars
Standard Deviation 90.26
15.0 Dollars
Standard Deviation 78.59
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
Change from Baseline at Week 4 (n=99,117)
-24.7 Dollars
Standard Deviation 222.07
4.4 Dollars
Standard Deviation 79.92
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
Week 8 (n=81,106)
146.2 Dollars
Standard Deviation 1113.58
16.7 Dollars
Standard Deviation 54.33
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
Change from Baseline at Week 8 (n=76,105)
-0.1 Dollars
Standard Deviation 71.11
7.5 Dollars
Standard Deviation 42.52
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
Week 12/ET (n=125,133)
113.0 Dollars
Standard Deviation 913.41
29.3 Dollars
Standard Deviation 177.85
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatments
Change from Baseline at Week 12/ET (n=119,128)
-47.8 Dollars
Standard Deviation 461.95
20.0 Dollars
Standard Deviation 180.70

SECONDARY outcome

Timeframe: Randomization Baseline, Weeks 4, 8, and 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Question 3b: nights stayed in the hospital

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
Week 12/ET (n=4,1)
24.8 Number of nights
Standard Deviation 49.50
0.0 Number of nights
Standard Deviation NA
standard deviation not applicable as n=1
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
Randomization Baseline (n=1,2)
0.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
0.0 Number of nights
Standard Deviation 0.00
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
Week 4 (n=4,0)
0.3 Number of nights
Standard Deviation 0.5
NA Number of nights
Standard Deviation NA
Mean and standard deviation not applicable as n=0
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
Change from Baseline at Week 4 (n=0,0)
NA Number of nights
Standard Deviation NA
Mean and standard deviation not applicable as n=0
NA Number of nights
Standard Deviation NA
Mean and standard deviation not applicable as n=0
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
Week 8 (n=1,1)
99.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
0.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
Change from Baseline at Week 8 (n=0,0)
NA Number of nights
Standard Deviation NA
Mean and standard deviation not applicable as n=0
NA Number of nights
Standard Deviation NA
Mean and standard deviation not applicable as n=0
Change From Randomization Baseline to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights Spent in Hospital
Change from Baseline at Week 12/ET (n=0,0)
NA Number of nights
Standard Deviation NA
Mean and standard deviation not applicable as n=0
NA Number of nights
Standard Deviation NA
Mean and standard deviation not applicable as n=0

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; the denominator for the percentage calculation is the number of participants who had both Screening value and Post Screening value for each treatment and visit. Imputation using the LOCF method.

Question 3a = In the past 4 weeks, have you been hospitalized due to chronic low back pain or any medication used for chronic low back pain?

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/Yes Week 4 (n=109,124)
0.9 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/No Week 4 (n=109,124)
2.8 Percentage of participants
0.8 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/Yes Week 4 (n=109,124)
2.8 Percentage of participants
1.6 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/No Week 4 (n=109,124)
93.6 Percentage of participants
97.6 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/Yes Week 8 (n=86,111)
0.0 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/No Week 8 (n=86, 111)
1.2 Percentage of participants
0.9 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/Yes Week 8 (n=86, 111)
2.3 Percentage of participants
1.8 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/No Week 8 (n=86, 111)
96.5 Percentage of participants
97.3 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/Yes Week 12/ET (n=130,136)
0.8 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
Yes/No Week 12/ET (n=130,136)
2.3 Percentage of participants
0.0 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/Yes Week 12/ET (n=130,136)
3.8 Percentage of participants
2.2 Percentage of participants
Percentage of Participants With Shift From Screening Period to the End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in Hospitalization Because of Low Back Pain as Assessed Using the HRU Questionnaire
No/No Week 12/ET (n=130,136)
93.1 Percentage of participants
97.8 Percentage of participants

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Question 1: number of office visits directly related to chronic low back pain or any medication used for chronic low back pain

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
Screening (n=121,136)
8.8 Number of visits
Standard Deviation 33.76
13.7 Number of visits
Standard Deviation 43.07
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
Week 4 (n=100,110)
6.5 Number of visits
Standard Deviation 24.35
5.3 Number of visits
Standard Deviation 37.99
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
Change from Screening at Week 4 (n=94,106)
0.8 Number of visits
Standard Deviation 28.99
-7.6 Number of visits
Standard Deviation 58.56
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
Week 8 (n=79,103)
22.8 Number of visits
Standard Deviation 179.55
3.3 Number of visits
Standard Deviation 13.46
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
Change from Screening at Week 8 (n=73,100)
16.7 Number of visits
Standard Deviation 188.74
-10.4 Number of visits
Standard Deviation 44.61
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
Week 12/ET (n=121,128)
19.2 Number of visits
Standard Deviation 153.80
4.2 Number of visits
Standard Deviation 15.38
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Number of Office Visits Related or Medication Used for Chronic Low Back Pain
Change from Screening at Week 12/ET (n=114,123)
13.2 Number of visits
Standard Deviation 159.55
-7.3 Number of visits
Standard Deviation 41.80

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Question 2: money (dollars) spent out-of-pocket on physical treatments in the past 4 weeks to manage chronic low back pain

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
Screening (n=126,138)
83.6 Dollars
Standard Deviation 277.98
85.6 Dollars
Standard Deviation 514.80
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
Week 4 (n=104,119)
19.9 Dollars
Standard Deviation 90.26
15.0 Dollars
Standard Deviation 78.59
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
Change from Screening at Week 4 (n=100,114)
-79.8 Dollars
Standard Deviation 315.79
-80.3 Dollars
Standard Deviation 497.56
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
Week 8 (n=81,106)
146.2 Dollars
Standard Deviation 1113.58
16.7 Dollars
Standard Deviation 54.33
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
Change from Screening at Week 8 (n=78,103)
56.9 Dollars
Standard Deviation 1174.87
-84.5 Dollars
Standard Deviation 593.49
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
Week 12/ET (n=125,133)
113.0 Dollars
Standard Deviation 913.41
29.3 Dollars
Standard Deviation 177.85
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Money Spent on Treatment for Chronic Low Back Pain
Change from Screening at Week 12/ET (n=120,128)
32.1 Dollars
Standard Deviation 944.71
-58.1 Dollars
Standard Deviation 563.65

SECONDARY outcome

Timeframe: Screening, Weeks 4, 8, and 12

Population: ITT Population; imputation using the LOCF method. n=number of participants analyzed for the given parameter at the specified timepoint.

Question 3b: nights stayed in the hospital

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
Screening (n=6,3)
0.0 Number of nights
Standard Deviation 0.00
0.3 Number of nights
Standard Deviation 0.58
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
Week 4 (n=4,0)
0.3 Number of nights
Standard Deviation 0.50
NA Number of nights
Standard Deviation NA
Mean and Standard deviation not applicable as n=0
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
Change from Screening at Week 4 (n=1,0)
0.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
NA Number of nights
Standard Deviation NA
Mean and Standard deviation not applicable as n=0
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
Week 8 (n=1,1)
99.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
0.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
Change from Screening at Week 8 (n=0,0)
NA Number of nights
Standard Deviation NA
Mean and Standard deviation not applicable as n=0
NA Number of nights
Standard Deviation NA
Mean and Standard deviation not applicable as n=0
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
Week 12/ET (n=4,1)
24.8 Number of nights
Standard Deviation 49.50
0.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
Change From Screening Period to End of Double-Blind Weeks 4, 8 and 12 (or Final Visit) in HRU Questionnaire: Nights in Hospital for Chronic Low Back Pain
Change from Screening at Week 12/ET (n=1,0)
0.0 Number of nights
Standard Deviation NA
Standard deviation not applicable as n=1
NA Number of nights
Standard Deviation NA
Mean and Standard deviation not applicable as n=0

SECONDARY outcome

Timeframe: Open-Label Period

Population: Titration Period Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Mean Oxycodone Average Daily Dose During the Open-Label Titration Period
45.8 mg
Standard Deviation 22.61

SECONDARY outcome

Timeframe: Open-Label Period

Population: Titration Period Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Mean Oxycodone Duration of Titration During the Open-Label Titration Period
31.0 days
Standard Deviation 12.24

SECONDARY outcome

Timeframe: Open-Label Period

Population: Titration Period Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Oxycodone Average Daily Dose During the Open-Label Titration Period
42.3 mg
Inter-Quartile Range 22.61 • Interval 16.0 to 163.0

SECONDARY outcome

Timeframe: Open-Label Period

Population: Titration Period Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Oxycodone Duration of Titration During the Open-Label Titration Period
35.0 days
Inter-Quartile Range 12.24 • Interval 1.0 to 56.0

SECONDARY outcome

Timeframe: Double-Blind Period

Population: Double-Blind Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Mean Oxycodone Average Daily Dose During the Double-Blind Treatment Period
70.1 mg
Standard Deviation 33.67
63.6 mg
Standard Deviation 34.02

SECONDARY outcome

Timeframe: Double-Blind Period

Population: Double-Blind Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Mean Oxycodone Duration of Treatment During the Double-Blind Treatment Period
62.7 days
Standard Deviation 30.20
70.9 days
Standard Deviation 27.80

SECONDARY outcome

Timeframe: Double-Blind Period

Population: Double-Blind Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Oxycodone Average Daily Dose During the Double-Blind Treatment Period
60.0 mg
Interval 20.0 to 152.0
59.6 mg
Interval 19.0 to 160.0

SECONDARY outcome

Timeframe: Double-Blind Period

Population: Double-Blind Safety Population

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Median Oxycodone Duration of Treatment During the Double-Blind Treatment Period
84.0 days
Interval 5.0 to 94.0
85.0 days
Interval 1.0 to 102.0

SECONDARY outcome

Timeframe: Blood samples were taken within +/-4 hours of the morning dose of ALO-02 at Week 6/Early Termination, Randomization Baseline

Population: Titration Period Safety Population; participants assessed at Week 6 had not been randomized to the Double-Blind Period; participants assessed at Randomization Baseline had been randomized to the Double-Blind Period.

Observed steady-state plasma concentration (Cobs) of oxycodone and noroxycodone.

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Titration Period
Oxycodone at Week 6/ET (n=77)
14.1 ng/mL
Standard Deviation 22.27
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Titration Period
Oxycodone at Randomization Baseline (n=267)
26.4 ng/mL
Standard Deviation 28.84
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Titration Period
Noroxycodone at Week 6/ET (n=77)
15.5 ng/mL
Standard Deviation 26.50
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Titration Period
Noroxycodone at Randomization Baseline (n=267)
29.9 ng/mL
Standard Deviation 42.04

SECONDARY outcome

Timeframe: Blood samples were taken within +/-4 hours of the morning dose of ALO-02 at Week 6/Early Termination, Randomization Baseline

Population: Titration Period Safety Population; participants assessed at Week 6 had not been randomized to the Double-Blind Period; participants assessed at Randomization Baseline had been randomized to the Double-Blind Period.

Cobs of naltrexone and 6-β-naltrexol

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=410 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Titration Period
Naltrexone at Week 6/ET (n=77)
4.6 pg/mL
Standard Deviation 19.02
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Titration Period
Naltrexone at Randomization Baseline (n=266)
14.6 pg/mL
Standard Deviation 81.73
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Titration Period
6-β-naltrexol at Week 6/ET (n=77)
82.0 pg/mL
Standard Deviation 305.91
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Titration Period
6-β-naltrexol at Randomization Baseline (n=266)
154.1 pg/mL
Standard Deviation 595.80

SECONDARY outcome

Timeframe: Blood samples were taken within +/-4 hours of the morning dose of study drug at Randomization Baseline, Weeks 4, 8, and 12

Population: Double-Blind Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Observed steady-state plasma concentration (Cobs) of oxycodone and noroxycodone

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Oxycodone at Baseline (n=127,140)
27.0 ng/mL
Standard Deviation 29.06
25.9 ng/mL
Standard Deviation 28.73
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Oxycodone at Week 4 (n=0,116)
NA ng/mL
Standard Deviation NA
Mean and standard deviation not applicable as n=0
23.3 ng/mL
Standard Deviation 26.90
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Oxycodone at Week 8 (n=0,107)
NA ng/mL
Standard Deviation NA
Mean and standard deviation not applicable as n=0
23.1 ng/mL
Standard Deviation 23.83
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Oxycodone at Week 12/ET (n=1,137)
0.0 ng/mL
Standard Deviation NA
Standard deviation not applicable as n=1
22.6 ng/mL
Standard Deviation 26.98
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Noroxycodone at Baseline (n=127,140)
33.1 ng/mL
Standard Deviation 48.84
27.1 ng/mL
Standard Deviation 34.67
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Noroxycodone at Week 4 (n=0,116)
NA ng/mL
Standard Deviation NA
Mean and standard deviation not applicable as n=0
25.5 ng/mL
Standard Deviation 40.54
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Noroxycodone at Week 8 (n=0,107)
NA ng/mL
Standard Deviation NA
Mean and standard deviation not applicable as n=0
26.2 ng/mL
Standard Deviation 34.38
Oxycodone and Noroxycodone Observed Steady-State Plasma Concentration During the Double-Blind Treatment Period
Noroxycodone at Week 12/ET (n=1,137)
0.0 ng/mL
Standard Deviation NA
Standard deviation not applicable as n=0
26.3 ng/mL
Standard Deviation 40.67

SECONDARY outcome

Timeframe: Blood samples were taken within +/-4 hours of the morning dose of study drug at Randomization Baseline, Weeks 4, 8, and 12

Population: Double-Blind Safety Population; n=number of participants analyzed for the given parameter at the specified timepoint.

Observed steady-state plasma concentration (Cobs) of naltrexone and 6-β-naltrexol

Outcome measures

Outcome measures
Measure
ALO-02 To Placebo
n=134 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 Participants
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
Naltrexone at Baseline (n=127,139)
24.9 pg/mL
Standard Deviation 116.41
5.3 pg/mL
Standard Deviation 16.48
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
Naltrexone at Week 4 (n=3,115)
0.0 pg/mL
Standard Deviation 0.0
3.4 pg/mL
Standard Deviation 14.65
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
Naltrexone at Week 8 (n=3,107)
0.0 pg/mL
Standard Deviation 0.0
2.9 pg/mL
Standard Deviation 11.13
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
Naltrexone at Week 12/ET (n=4,137)
0.0 pg/mL
Standard Deviation 0.0
3.0 pg/mL
Standard Deviation 12.67
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
6-β-naltrexol at Baseline (n=127,139)
216.0 pg/mL
Standard Deviation 800.32
97.5 pg/mL
Standard Deviation 300.17
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
6-β-naltrexol at Week 4 (n=3,115)
0.0 pg/mL
Standard Deviation 0.0
86.1 pg/mL
Standard Deviation 315.42
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
6-β-naltrexol at Week 8 (n=3,107)
0.0 pg/mL
Standard Deviation 0.0
48.3 pg/mL
Standard Deviation 156.42
Naltrexone and 6-β-naltrexol Observed Steady-State Plasma Concentration During the Double Blind Treatment Period
6-β-naltrexol at Week 12/ET (n=4,137)
0.0 pg/mL
Standard Deviation 0.0
55.6 pg/mL
Standard Deviation 163.41

Adverse Events

Open ALO-02

Serious events: 3 serious events
Other events: 186 other events
Deaths: 0 deaths

ALO-02 To Placebo

Serious events: 2 serious events
Other events: 26 other events
Deaths: 0 deaths

ALO-02 To ALO-02

Serious events: 5 serious events
Other events: 41 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Open ALO-02
n=410 participants at risk
Participants received AL0-02 extended-release capsules, orally PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator.
ALO-02 To Placebo
n=134 participants at risk
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 participants at risk
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Musculoskeletal and connective tissue disorders
Arthritis
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders
Costochondritis
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Vascular disorders
Intermittent claudication
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.75%
1/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Vascular disorders
Peripheral arterial occlusive disease
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.75%
1/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Cardiac disorders
Atrial flutter
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Cardiac disorders
Myocardial infarction
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Bronchitis
0.24%
1/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Urinary tract infection
0.24%
1/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications
Drug administration error
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications
Road traffic accident
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.75%
1/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Hepatobiliary disorders
Cholecystitis
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Hepatobiliary disorders
Cholelithiasis
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Metabolism and nutrition disorders
Cholesterosis
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Pregnancy, puerperium and perinatal conditions
Unintended pregnancy
0.00%
0/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Psychiatric disorders
Depression
0.24%
1/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Psychiatric disorders
Suicide attempt
0.24%
1/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
0.24%
1/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.

Other adverse events

Other adverse events
Measure
Open ALO-02
n=410 participants at risk
Participants received AL0-02 extended-release capsules, orally PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator.
ALO-02 To Placebo
n=134 participants at risk
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, underwent a double-blind gradual taper of ALO-02 to discontinue use over the first 2 weeks, and then received double-blind placebo capsules PO BID for 10 weeks.
ALO-02 To ALO-02
n=146 participants at risk
Participants received AL0-02 extended-release capsules PO BID at total daily doses of oxycodone from 20 to 160 mg in the Open-Label Conversion and Titration Period for 4 to 6 weeks; titration was at the discretion of the investigator. If a participant met protocol-defined treatment response criteria at the end of open-label Week 4, 5, or 6, the participant was randomized into the Double-Blind Treatment Period, received a dummy-taper but continued to receive double-blind ALO-02 capsules PO BID at a fixed dose (specifically the ALO-02 fixed dose that had not changed with the 7 consecutive days prior to randomization) for 12 weeks.
Musculoskeletal and connective tissue disorders
Back pain
1.2%
5/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
6.0%
8/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
2.1%
3/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Constipation
14.9%
61/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
2.2%
3/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
3.4%
5/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Diarrhoea
2.2%
9/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
4.5%
6/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
5.5%
8/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Nausea
20.5%
84/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
3.7%
5/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
14.4%
21/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Vomiting
9.0%
37/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
3.0%
4/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
6.2%
9/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Dizziness
5.9%
24/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.75%
1/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
4.1%
6/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Headache
7.3%
30/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
5.2%
7/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
1.4%
2/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Somnolence
8.8%
36/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.75%
1/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.68%
1/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
Skin and subcutaneous tissue disorders
Pruritus
6.3%
26/410 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
0.00%
0/134 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.
1.4%
2/146 • From the time of informed consent up to and including 28 calendar days after the last administration of the investigational product.
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60